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ABSTRACT

The aims of this study were to 1) describe endocrine therapy (ET) non-initiation,
non-adherence, and duration by age, race, and temporal trend; 2) identify demographic,
clinical, and pharmaceutical factors that are associated with an individual’s ET usage;
and 3) understand from the survivor perspective which modifiable factors could have the
greatest impact on the likelihood of ET continuation.
This study utilized a convergent parallel mixed methods design. The sample
included female South Carolina (SC) residents ages 18-64 at diagnosis with hormone
receptor-positive breast cancer. SC Central Cancer Registry incidence data linked with
South Carolina Medicaid data (N=3,830) were along with focus groups in four SC
locations (N=22). Age, race, relative risk and median duration of ET use were compared.
Temporal trends in ET non-initiation, non-adherence, and duration were observed using
linear and logistic regression models, controlling for age and race. A series of multiple
regression models were built to explore the association of demographic, clinical, and
pharmaceutical factors with ET usage duration. Qualitative data analysis was completed
by a three-member research team using an inductive narrative approach. Themes were
examined by participant decision to continue or discontinue ET.
Fifty three percent of women in the sample did not initiate ET, with highest noninitiation rates among African Americans and survivors under age 50. Of those who did
initiate ET, 42% were non-adherent with a median ET usage duration of 37 months.
Twenty one percent of initiators continued taking ET for five years or more. There was
no change in the odds of ET non-initiation from 2000 – 2004. The odds of ET non-

ii

initiation decreased from 2005 – 2009 but then increased from 2010 – 2014. There was
no change in the odds of ET non-adherence from 2000 – 2006, but from 2007 – 2012, the
odds of ET non-adherence decreased each year. The average ET usage duration was
increasing from 2000 – 2006 but decreasing from 2006 – 2012.
Multiple linear regression analysis showed that none of the demographic or
clinical factors tested were significantly associated with ET usage duration. The type of
ET taken as well as receipt of the prescriptions that could have been used to alleviate side
effects were significantly associated. Participants’ feedback centered on a risk vs. benefit
analysis unique to the individual survivor. Main themes included the importance of an
open, honest patient/provider relationship and the need for personal information seeking
and affirmation in the decision to take ET. There was clear support for the utility of
multidisciplinary cancer care teams and incorporating integrative approaches.
This study provides a realistic picture of the challenges associated with ET usage
among South Carolina Medicaid breast cancer patients. It particularly highlights more
opportunity for improvement in ET initiation, adherence, and duration among younger
women of lower socioeconomic status. Our study also highlights the potential value of
concurrent prescriptions for improving ET usage duration, with an optimal intervention
point before 14 months post ET initiation. Further research is needed to test
pharmacologic interventions that may significantly increase ET duration as well as other
non-pharmacologic strategies for side effect management. Research employing patientcentered perspectives is imperative. Novel and practical patient-centered interventions in
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research exploring openness in the patient/provider relationship, survivor information
seeking practices, multidisciplinary teams, and integrative approaches are needed.
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CHAPTER ONE
INTRODUCTION
Overview
It is well known that breast cancer is the most common type of cancer in the
United States, accounting for almost 15% of all new cancer cases and 6.8% of all cancer
deaths in 2016 (“Cancer Among Women,” 2016; “Cancer of the Breast,” 2016).
Following surgery, radiation therapy, and/or chemotherapy, a woman with Stage 0-III
hormone receptor-positive breast cancer is typically prescribed endocrine therapy (ET)
for five years or longer as part of initial treatment (“Hormonal Therapy,” 2016; “Ten
Years,” 2014). The purpose of ET is to reduce a woman’s risk of breast cancer
recurrence. Taking ET (Tamoxifen or an aromatase inhibitor) as prescribed for five years
can reduce the risk of recurrence by 40% and death by one-third (Early Breast Cancer
Trialists' Collaborative Group [EBCTCG], 2005).
Research and clinical practice confirm that rates of ET initiation (i.e. filling the
first prescription), adherence (i.e. following the provider’s recommendations day-to-day
regarding the timing, dosage, and frequency of the ET), and continuation (i.e. the act of
continuing ET for the prescribed duration) are quite low (Cramer et al., 2008; Hershman
et al., 2011; Partridge, Wang, Winer, & Avorn, 2003; Wheeler et al., 2014). Studies
conducted in the North Carolina and New York Medicaid populations showed noninitiation rates around 50% without intervention (Wagner et al., 2016; Wheeler et al.,
2014). A systematic review by Murphy et al. (2012) showed that adherence ranged from
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41–72% and discontinuation ranged from 31–73%, measured at the end of 5 years of
treatment.
Knowledge of the population affected by ET non-initiation, non-adherence, and
early discontinuation in South Carolina is limited, as is knowledge of how to improve the
ET experience for patients, both in South Carolina and across the nation. The few studies
that have addressed interventions showed little to no improvement over usual care
(Hurtado-de-Mendoza, Cabling, Lobo, Dash, & Sheppard, 2016; Ekinci et al., 2018). The
overall aim of this research is to inform the development of future interventions by 1)
describing ET non-initiation, non-adherence, and duration by age, race, and temporal
trend and 2) identifying demographic, clinical, and pharmaceutical factors that are
associated with an individual’s ET usage duration for South Carolina Medicaid-enrolled
women who had hormone receptor-positive breast cancer diagnosed between 2000 and
2014. This third aim of this research is to inform future interventions by understanding,
from the survivor perspective, which modifiable factors could have the greatest impact on
the likelihood of ET continuation.

Problem Statement
ET discontinuation and non-adherence rates remain high despite the use of ET for
decades as the primary means of reducing the risk of breast cancer recurrence in women
with hormone receptor-positive Stage 0-III disease (EBCTCG, 2005; Reynolds &
Higgins, 2013). The only known published research regarding ET usage among South
Carolina women was conducted among Medicaid enrollees by Wu and Lu (2013) and
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Felder et al. (2016). Wu and Lu examined the association between adherence to hormone
therapy and healthcare costs from 2000-2008 and found no significant difference in total
healthcare costs between the adherent and non-adherent women. Felder et al. (2016)
studied racial differences in the receipt of ET among patients in one health care system
and found no significant differences by race but overall low usage rates.
The purpose of the proposed study is to further expand on the work of Wu and Lu
(2013) and Felder et al. (2016) to examine the ET non-initiation, non-adherence, and
duration of SC women recipients diagnosed with hormone receptor-positive breast cancer
after 2000 and to ultimately inform a patient-centered intervention to improve ET usage.
Specifically, the aims of this study are 1) to describe ET non-initiation, nonadherence, and duration by age, race, and temporal trend and 2) to identify
demographic, clinical, and pharmaceutical factors that are associated with an
individual’s ET usage duration for South Carolina Medicaid-enrolled women who
had hormone receptor-positive breast cancer diagnosed between 2000 and 2014; and
3) to understand from the survivor perspective which modifiable factors could have
the greatest impact on the likelihood of ET continuation. It is imperative that research
be conducted that employs a patient-centered perspective. The knowledge gained through
further study can be integrated in developing future patient-centered interventions to
enhance the ET experience for breast cancer survivors.
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Theoretical Framework
The Health Belief Model was used as the theoretical framework to explain what is
currently known about ET usage and informed the study design. The Health Belief Model
was developed in the 1950s by Hochbaum, Rosenstock, and Kegels of the U.S. Public
Health Services (“Health Belief Model,” n.d.). Since then, it has been widely used to
study various preventive health and clinic use behaviors among many populations
(Baghianimoghadam et al., 2013; Farma, Jalili, Zareban, Pour, 2014; Holwerda, 2000;
VanDyke & Shell, 2016; Wang et al., 2014).
The study used the original Health Belief Model, which consists of six major
constructs: perceived susceptibility, perceived seriousness, perceived benefits, perceived
barriers, modifying variables, and cues to action. In the study context, these constructs
were briefly defined as follows (Hayden, 2013; “Health Belief Model,” n.d.):


Perceived susceptibility: A woman’s assessment of the chances of breast
cancer recurrence



Perceived seriousness: A woman’s assessment of the severity of breast cancer
recurrence



Perceived benefits: A woman’s degree of belief in the efficacy of ET in
reducing breast cancer recurrence



Perceived barriers: A woman’s assessment of the costs of ET continuation and
adherence



Modifying variables: Personal factors that affect ET usage



Cues to action: Factors that help “activate readiness” in a woman taking ET
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See Appendix A for a detailed diagram of the Health Belief Model applied to this
study on ET usage among South Carolina breast cancer survivors.
The study also employed grounded theory in interpreting its qualitative findings.
This theory was first published by Glaser & Strauss in 1967 (Cohen & Crabtree, 2006).
Grounded theory is an empirical, inductive, systematic process in which theoretical
insights are generated from the data collected and are not established prior to the study;
however, it is possible that the findings may reveal that an established theory is the most
fitting for their interpretation (Chapman, Hadfield, & Chapman, 2014; Cohen & Crabtree,
2006; Hussein, Hirst, Salyers, & Osuji, 2014). For example, it was hypothesized that
based on cancer survivorship and medication adherence literature, Michel’s Uncertainty
in Illness Theory, Theory of Planned Behavior, a quality of life theory, or a stress and
coping theory may be suited to the findings. Nevertheless, in keeping with the principles
of grounded theory, this was not assumed nor determined until data analysis (Hussein,
Hirst, Salyers, & Osuji, 2014). As pointed out by Achora and Matua (2016), although
grounded theory was employed, the research questions, data collection methods, and
coding processes were clearly specified and explained prior to data collection.
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CHAPTER TWO
LITERATURE REVIEW
To provide background and context for the study, several pertinent topics were
surveyed in the literature including breast cancer epidemiology; the role and history of
ET in breast cancer treatment; the problem of ET non-initiation, non-adherence, and
discontinuation; and existing interventions.

Breast Cancer Epidemiology
The human body is composed of trillions of cells that grow and divide to form
new cells that take the place of old or damaged cells as they die (“What is Cancer?,”
2015). “Cancer” is a broad term describing a condition in which genetic changes cause
cells to grow and divide endlessly, even though not needed by the body (“What is
Cancer?,” 2015). These additional cells can form tumors that are usually named for the
part of the body where they originate (“Breast Cancer Facts,” 2015). For example, breast
cancers begin in parts of the breast, usually the ducts or lobules (“Breast Cancer Facts,”
2015).
Female breast cancer is currently the most common type of cancer in the United
States, followed by lung and bronchus cancer, prostate cancer, colon and rectum cancer,
and bladder cancer. In 2016, there were approximately 246,660 new cases of female
breast cancer, which accounted for 14.6% of all new cancer cases, and there were 40,450
estimated deaths from female breast cancer, which accounted for 6.8% of all cancer
deaths (“Cancer of the breast,” 2016). From 2006-2012, 89.7% of persons with female
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breast cancer survived five years or more post-diagnosis (“Cancer of the breast,” 2016).
From 2009-2013, female breast cancer was most commonly diagnosed among women
ages 55-64 (25.7%), and women ages 45-74 accounted for almost 70% of all new breast
cancer cases (“Cancer of the breast,” 2016). The female breast cancer incidence rate from
2009-2013 was highest among white women (128.0 per 100,000), followed closely by
black women (125.2 per 100,000); however, the number of deaths was higher for black
women (29.6 per 100,000) compared to white women (21.0 per 100,000) (“Cancer of the
Breast,” 2016).
South Carolina ranks 20th for female breast cancer incidence when compared to
the rest of the United States (Bolick & Clugstone, 2016). From 2009-2013, South
Carolina experienced the most new cases of lung cancer, followed by female breast
cancer (Bolick & Clugstone, 2016). On average, 3,606 new cases of female breast cancer
occurred annually in the state from 2009-2013 with an incidence rate 125.9 per 100,000
(Bolick & Clugstone, 2016). The American Cancer Society expected that South Carolina
would experience 4,250 new cases of breast cancer in 2017 (“Cancer Facts,” 2017).
South Carolina has a higher female breast cancer mortality rate (2009-2013)
compared to the U.S., ranking 14th when compared to the rest of the nation’s states (22.4
per 100,000 versus 21.5 per 100,000) (“Breast Cancer in South Carolina,” 2016). Similar
to national trends, the breast cancer mortality rate is higher for South Carolina black
women compared to white women (28.7 per 100,000 versus 20.3 per 100,000) (“Breast
Cancer in South Carolina,” 2016).
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With advances in breast cancer screening and treatment, the population of female
breast cancer survivors in the United States continues to grow and was estimated at
3,560,570 as of January 2016 (“Cancer Treatment & Survivorship,” 2016). This
population is expected to total 4,571,210 by 2026 (“Cancer Treatment & Survivorship,”
2016). Female breast cancer survivors can experience long-term effects from their
surgical, radiation, or chemotherapy treatments, including numbness, tingling, or
tightness in the chest wall, arms, or shoulders; persistent nerve pain in the chest wall,
armpit, and/or arm after surgery; or other types of chronic pain (“Cancer Treatment &
Survivorship,” 2016). In addition, breast cancer treatments can affect a woman’s fertility
and menopausal status and put a woman at an increased risk for osteoporosis (“Cancer
Treatment & Survivorship,” 2016).
An important issue for breast cancer survivors is the risk of cancer recurrence.
Once the initial cancer is treated, there remains the risk of the cancer recurring either
locally in the breast or metastasizing (i.e. spreading to other parts of the body). The
amount of risk for secondary cancers depends on many different factors related to the
original cancer and the initial treatment. Some of these factors can include the hormone
receptor status, human epidermal growth factor receptor 2 (HER2), whether the tumor
margins and lymph nodes contain cancer cells, whether a woman had a lumpectomy (i.e.
breast conserving surgery) and radiation therapy versus a mastectomy, and whether a
woman had chemotherapy (“What are the risks,” 2016). For instance, for women who
have a lumpectomy and complete radiation therapy, the risk of local recurrence within ten
years is between three to fifteen percent (Arvold et al., 2011). For women who have a
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mastectomy and whose lymph nodes do not contain cancer, the chance of local
recurrence in five years is approximately six percent (Celik, Aydoğan, Yilmaz, Yaşar, &
Müslümanoğlu, 2016).

Role and History of Endocrine Therapy in Breast Cancer Treatment
During a biopsy or surgery, cancer cells are tested to determine if they have
estrogen or progesterone receptors (“Breast Cancer Hormone Receptor,” 2016). Sixty to
seventy-five percent of cancers are hormone receptor-positive, meaning that the cells test
positive for estrogen (“Breast Cancer Hormone Receptor,” 2016; Burstein et al., 2014).
Knowing this status is important in determining the treatment options because after the
initial chemotherapy, radiation, and/or surgery, if the cancer is hormone receptorpositive, a woman can be prescribed ET to reduce her risk of breast cancer recurrence.
Two types of ET that can be used to reduce the risk of breast cancer recurrence
for women with hormone receptor-positive cancer are Tamoxifen and aromatase
inhibitors. Tamoxifen is a selective estrogen receptor modulator and blocks estrogen
receptors in breast cancer cells (“Hormone Therapy,” 2016) and is typically prescribed
for pre-menopausal women. Aromatase inhibitors (Letrozole/Femara,
Anastrozole/Arimidex, and Exemestane/Aromasin) are given to women whose ovaries no
longer produce estrogen (i.e. usually post-menopausal women or women receiving
ovarian ablation). Aromatase inhibitors block aromatase, an enzyme in fat tissue, from
making estrogen (“Hormone Therapy,” 2016).
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The beginnings of understanding the role that estrogen plays in breast cancer can
historically be traced back to the late 1800s (“Evolution of Cancer,” 2014; Jones &
Buzdar, 2004). Tamoxifen was originally introduced in 1967 as an antifertility agent in
rats and was proposed for long term adjuvant therapy ten years later (Jordan, 2006;
Maximov, Lee, & Jordan, 2013). In 1977, research targeting the aromatase enzyme also
began (Maximov, Lee, & Jordan, 2013). Selective aromatase inhibitors were first
reported in 1973 and began testing in clinical trials in the 1990’s (Jordan & Brodie,
2007).
For decades, Tamoxifen was prescribed for five years as standard treatment. In
2014, the American Society of Clinical Oncology (ASCO) convened a committee to
conduct a systematic review to examine evidence from 2009 through 2013 trials
regarding extending the duration of Tamoxifen from five to ten years (Burstein et al.,
2014). The results of the MA.17R trial were also released in 2016 and showed benefits of
taking aromatase inhibitors for up to ten years over five years (Goss et al., 2016). As of
2016, ASCO and the National Comprehensive Cancer Network generally recommend the
following regimens for women with Stage I-III breast cancer (“Hormonal Therapy for
Early-Stage,” 2016; NCCN Guidelines, 2014; NCCN Guidelines, 2016):


Premenopausal women should take Tamoxifen for five years possibly combined
with ovarian suppression or ablation. At the end of five years, if the woman is still
premenopausal, she should consider taking Tamoxifen for another five years or
stop taking ET. At the end of the first five years, if the woman is postmenopausal,
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the woman could take aromatase inhibitors for five years or consider taking
Tamoxifen for another five years.


An alternate to Tamoxifen as initial treatment for premenopausal women is to
take an aromatase inhibitor for five years with ovarian suppression or ablation.



Postmenopausal women have the option to take an aromatase inhibitor for five
years, consider Tamoxifen for ten years if aromatase inhibitors are not an option,
or take Tamoxifen for a period of time, followed by an aromatase inhibitor until
five or ten years of ET duration is reached.

Problem of Endocrine Therapy Non-initiation, Non-adherence, and Discontinuation
Numerous studies have been conducted to examine the problem of ET noninitiation, non-adherence, and discontinuation. These studies estimate the percentage of
patients who do not initiate, are non-adherent, or discontinue as well as identify risk
factors for non-initiation, non-adherence, or discontinuation. Studies conducted in
Medicaid populations in New York and North Carolina showed non-initiation rates
around 50% without intervention (Wagner et al., 2016; Wheeler et al., 2014). The results
of four major systematic reviews will be presented.
Gotay and Dunn (2011) conducted a systematic review of studies published
between 2007 and 2011 examining ET use in clinical practice with a sample size of at
least 100. Fourteen studies met the inclusion criteria. The review showed that adherence
rates after one year of ET usage ranged from 77–88%, and adherence rates in years four
and five ranged from 27–49%. Middle-aged women (e.g. 50–69 years) appeared to be
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most adherent. Low social support was negatively associated with adherence. Being
married produced mixed results. Greater comorbidity and drug cost were also negatively
associated with adherence. Side effects such as hot flashes, mood disturbances, and
muscle aches largely contributed to patients not taking ET as did lack of communication
from their providers regarding the importance of taking ET. Studies that examined use of
both Tamoxifen and aromatase inhibitors reported better adherence to aromatase
inhibitors, although the groups were different based on important factors such as age.
Murphy et al. (2012) conducted a systematic review to examine literature from
1998-2012 related to ET adherence and continuation in routine clinical settings,
excluding clinical trials. Twenty-nine studies met the review inclusion criteria. The
review showed that the prevalence of adherence ranged from 41–88% among Tamoxifen
users and 50–91% for aromatase inhibitor users (Murphy et al., 2012). The percentage of
Tamoxifen users who discontinued treatment ranged from 15–20% in the first year of
therapy to 31–60% at the end of five years. The percentage of aromatase inhibitor users
who discontinued treatment ranged from 5–25% during the first two years of therapy.
Studies that examined users of both Tamoxifen and aromatase inhibitors aggregately
showed discontinuation rates that ranged from 32–73% at the end of five years.
Prospective studies describing Tamoxifen discontinuation revealed rates of 21%, 15%,
and 31% at the end of 27, 33, and 63 month study periods, respectively. The systematic
review also showed that women who originally took Tamoxifen and switched to an
aromatase inhibitor after two to three years were less likely to adhere to treatment. The
following factors were found to be negatively associated with adherence: Extremes of age
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(i.e., older or younger), increasing out-of-pocket costs, follow-up care with a general
practitioner (vs. cancer specialist), and treatment side effects. The following factors were
found to be positively associated with adherence: taking more medications at baseline,
referral to an oncologist, and earlier year at diagnosis. Low social support was found to
be negatively associated with continuation.
Chlebowski, Kim, and Haque (2014) conducted a comprehensive literature review
that showed the following factors were associated with ET discontinuation: side effects,
higher comorbidity, financial considerations or low socioeconomic status, very young or
older age, lack of provider recommendation, perception of low risk of recurrence, lack of
social support, follow-up care with general practitioner vs. oncologist, African American
race/ethnicity, cigarette smoking, and alcohol use. The presence of anxiety/depression
was linked to better adherence. Findings regarding adherence stratified by race/ethnicity
were mixed.
Roberts, Wheeler, and Reeder-Hayes (2015) conducted a systematic review of
literature to determine racial/ethnic and socioeconomic disparities in ET adherence. The
literature search included studies from 1978-2014. Fourteen articles met the inclusion
criteria. Half of the articles showed there was significant racial/ethnic variation in ET
usage, with four of the studies showing that Black women were less likely to initiate or
adhere to ET than women of other racial/ethnic groups. Half of the articles showed there
was no effect of race/ethnicity on ET use. Across racial/ethnic groups, side effects were
among the top reported barriers to ET use. The relationship between cost and ET use is
unclear, as results varied widely among studies. Referral to a medical oncologist was

13

positively associated with ET use. Among low-income women, higher perceived efficacy
of patient-physician interactions and the quality of patient-provider communication was
associated with increased ET continuation. Social support was not strongly associated
with ET use.
Though the systematic reviews included qualitative studies, a two pertinent
qualitative studies will be highlighted individually that are especially relevant to the
proposed study. J Van Londen et al. (2015) conducted focus groups with fourteen breast
cancer survivors taking adjuvant ET at the University of Pittsburgh. Results showed that
initially, the women did not view taking ET as a decision but felt it something necessary
for their future health. Once unanticipated symptoms occurred (including vasomotor
symptoms, sexual dysfunction, insomnia, fatigue, cognitive dysfunction, pain, functional
limitations, mood disturbance, and anxiety), women were uncertain about the cause of
their symptoms, felt their friends and families could not relate, and felt that talking with
their providers about the symptoms was difficult and could be seen as a sign of
emotional/psychological problems. Frustration ensued, and women expressed
dissatisfaction with the symptom management information from healthcare providers and
found few effective and tolerable symptom management strategies. These issues caused
the women to rethink their decision to take ET and to reweigh the pros and cons of
whether the reduced risk of recurrence was worth losing their current quality of life.
Pellegrini et al. (2010) conducted semi-structured interviews with 34 women aged
35-65 at two French cancer centers. All participants were breast cancer patients and had
been prescribed Tamoxifen. Findings showed that women confused the hormonal/anti-
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hormonal effects of Tamoxifen and how it was related to contraceptive pills and hormone
replacement therapy. Many women admitted lacking knowledge about Tamoxifen’s
action and expressed doubts as to its necessity. A common theme women expressed was
a dislike of drugs and a fear that Tamoxifen could cause other types of cancer. Women
also expressed concern for the lack of treatment options for side effects, especially hot
flashes and tiredness, and the need for clarification about the causes of perceived
menopausal symptoms. Women said they received conflicting messages from their
oncologist, other patients, and the internet. Women shared the distress and tension they
felt while taking Tamoxifen because of the paradoxical situation that the drug’s purpose
was to save life but it was causing their youthful looks and femininity to diminish.
Research is needed on modifiable factors associated with ET use as well as the
development of behavioral and educational interventions intended to improve initiation,
adherence, and continuation (Chlebowski, Kim, & Haque, 2014; Murphy et al., 2012).

Existing Interventions
Hurtado-de-Mendoza et al. (2016) published what the authors describe as the first
systematic literature review examining behavioral interventions aimed at improving
hormone therapy adherence. Five articles met the study inclusion criteria. The Patient’s
Anastrozole Compliance to Therapy (PACT) was used in three of the studies. PACT
employed educational materials (i.e. nine pamphlets and ten personal letters) about breast
cancer, treatments, medication side effects, strategies for enhancing adherence, and
information about diet and physical exercise as well as monthly reminders about
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medication adherence. Variations of PACT were tested in three of the five studies, which
were conducted in Germany, eighteen countries, and China, respectively. Another study
consisted of a three-arm randomized controlled trial. Participants in one arm received
personalized motivational reminder letters containing information including the
importance and impact of disease, effects of AIs, and nurse contacts to answer questions
as well as a breast cancer leaflet. Those assigned to the second arm received telephone
calls from a nurse who conducted motivational interviewing and provided motivation,
reminders, and individualized information regarding the patient’s specific problems.
Finally, a third intervention used a two-arm randomized trial design to assign patients to
an enhanced standard of care arm with written resource patient navigation information or
to a written information plus one structured phone interview by a patient navigator. None
of the interventions tested in the five studies significantly improved adherence or
continuation when compared to usual care.
Studies have also tested novel communication strategies for patients and
providers. Epstein et al. (2015) developed and tested a bi-directional text messaging
application that simultaneously assesses patient adherence to ET and provides real-time
feedback to the provider. The pilot study of 62 patients showed found the application
helpful, easy to use, and not time consuming, with none of the patients discontinuing ET
compared to nine percent of historical controls.
Another e-Health intervention is currently taking place in Montreal, Canada with
results expected by June of 2018 (Meguerditchian et al., 2016). This e-Health tool
integrates real-time analysis of health administrative claims data to provide point-of-care
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decision support for clinicians. The purpose of the study is to determine the effectiveness
of the intervention in reducing rates of ET discontinuation, to understand patient-level
factors related to ET discontinuation, and to assess the integration of e-Health alerts
regarding deviations from best practices in ET administration by cancer care teams.
Some interventions focus on relieving side effect symptoms and increasing
quality of life through various means including exercise, sleep aids, and mindfulness.
These studies typically have not measured whether the improvement in side effect
symptoms or quality of life actually has improved ET usage. Hojan, Molinska-Glura, and
Milecki (2012) studied the results of an aerobic exercise program for a sample of fortyone premenopausal women. The program began six months after ET initiation. The
program took place at the Rehabilitation Ward in the Greater Poland Cancer Centre.
Body composition, body physique, and Quality of Life were evaluated before and after
six, 12, and 18 months of ET using dual-energy x-ray absorptiometry (DXA) scans,
anthropometric measurement techniques, and questionnaires from the European
Organization for Research and Treatment of Cancer, respectively. In the eighteenth
month of the study, results showed a significant increase in overall quality of life and
functioning levels, improved positive body image, and a reduction in symptom levels.
The Yale Fitness Intervention Trial sought to determine the effects of a twelvemonth aerobic-resistance exercise intervention compared to a home-based physical
activity group (Knobf et al., 2016). Seventy-six patients were randomized to the exercise
intervention, and 78 were randomized to the home group. When compared at one year,
participants on Tamoxifen or no ET did not lose a significant amount of bone mineral
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density except in the femoral neck, but participants on aromatase inhibitors had
significant bone mineral density loss at all sites. Thus, the intervention proved ineffective
for patients taking aromatase inhibitors.
Marshall-McKenna et al. (2015) studied the effect of a cool pad pillow topper
versus standard care for women taking ET suffering from hot flushes and insomnia.
Thirty-seven women were randomized to the intervention arm, and thirty-eight were
randomized to the control arm. Sleep efficiency score increased twice as much in the
intervention arm between two to four weeks of the intervention. There was also
significantly greater reductions in hot flushes and the depression score for the
intervention arm.
Mebis et al. (2016) reported on an eight-week Mindfulness-Based Stress
Reduction (MBSR) intervention provided to twenty newly diagnosed breast cancer
patients taking Tamoxifen. MBSR is a structured group intervention that is based on
meditation and its daily life application. MBSR has proven effective when used to help
cancer patients but had not yet been tested specifically with ET patients. Mebis et al.
(2016) found that after receiving the MBSR intervention, the depression anxiety stress
scale scores of the twenty patient cohort significantly decreased; however, the quality of
life scale scores also decreased during the intervention but were improved over baseline
six months post-intervention.
Future research should test these interventions’ impact on ET usage. Other
approaches for improving ET adherence and continuation have been suggested such as
enhancing nurse-patient communication regarding ET; clinical approaches to early

18

recognition and treatment of genitourinary side effects of ET; and utilizing patient
support groups, and online communities and blogs; but these have yet to be tested. (Gotay
& Dunn, 2011; Miaskowski, Shockney, & Chlebowski, 2008; Sousa et al., 2017).
Although the results of systematics reviews show little to no improvement in ET
usage, there are certainly elements of interventions that have proven successful in
decreasing side effects or increasing quality of life that have potential to improve ET
usage. More research is needed to better understand how and when to intervene to
improve ET usage among South Carolina women. More information is required to inform
future practice and intervention, including which populations are most in need, how ET
usage has changed over time, factors that are associated with longer ET usage, and which
modifiable elements patients say could be the most useful.
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CHAPTER THREE
METHODOLOGY

Research Questions
This dissertation research focused on female, South Carolina residents diagnosed
with stage 0-III or unstaged hormone receptor-positive breast cancer and who were age
18-64 at diagnosis. This research was guided by six primary research questions:
AIM 1: To describe ET non-initiation, non-adherence, and duration by age,
race, and temporal trend
Question 1: How do rates of ET non-initiation, non-adherence, and duration vary
by age and race?
Hypothesis 1: ET non-initiation, non-adherence, and duration rates are worse
among younger women and women of African American race.
Question 2: How have rates of ET non-initiation, non-adherence, and duration
changed during the study period?
Hypothesis 2: There has been no change over the study period in ET noninitiation, non-adherence, and duration.
AIM 2: To identify demographic, clinical, and pharmaceutical factors that
are associated with an individual’s ET usage duration
Question 3: Which demographic, clinical, and pharmaceutical factors are
associated with an individual’s ET usage duration?
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 Demographic: race (white, African American, or other), age at diagnosis, marital
status (married/unmarried), and rural/urban residency status (2013 Rural-Urban
Continuum Codes)
 Clinical: SEER summary breast cancer stage, receipt of chemotherapy (yes/no),
and receipt of radiation therapy (yes/no)
 Pharmaceutical: Type of endocrine therapy (Tamoxifen, Anastrozole/Arimidex,
Exemestane/Aromasin, Letrozole/Femara, switched between aromatase inhibitors,
switched between Tamoxifen and aromatase inhibitors), and filled alpha-agonist
hypertensives prescription (yes/no), filled antidepressants prescription (yes/no),
filled anticonvulsants prescription (yes/no), filled adrenals prescription (yes/no),
filled nonsteroidal anti-inflammatory agents prescription (yes/no), filled antiinflammatory agents prescription (yes/no), and filled vitamins prescription (B, C,
D, K, and/or multivitamin) (yes/no).
Hypothesis 3: Women taking Tamoxifen will have lower ET usage duration than
women taking aromatase inhibitors. Filling prescriptions for drugs known to alleviate
side effects will be associated with increased ET usage duration.
AIM 3: To understand from the survivor perspective which modifiable
factors could have the greatest impact on the likelihood of ET continuation.
Question 4: What are women’s’ perceptions regarding susceptibility/severity of
breast cancer recurrence?
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Hypothesis 4: Women’s susceptibility to breast cancer recurrence will be
influenced by provider-patient communication. Women will perceive recurrence as
severe but also be influenced by short-term quality of life preferences.
Question 5: What are the perceived benefits/barriers to ET continuation?
Hypothesis 5: Side effects will emerge as a major perceived barrier to ET
continuation.
Question 6: What are the cues to action that encourage and support ET
continuation?
Hypothesis 6: Provider-patient communication will play a key role in supporting
ET continuation.

Overall Research Design
This study utilized a convergent parallel mixed methods design. A mixed methods
design was chosen because the quantitative and qualitative approaches were structured to
answer different but complementary questions. By choosing the convergent parallel
design, the quantitative and qualitative data collection and analyses were able to take
place simultaneously (Creswell & Clark, 2007). Their results were combined to provide a
richer multidimensional understanding of the problem of ET non-initiation, nonadherence, and discontinuation than one approach alone (Curry & Nunez-Smith, 2014).
Figure 3.1 illustrates the mixed methods design of the proposed study.
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Figure 3.1 Convergent parallel mixed methods study design

The methodology for the quantitative and qualitative branches of the study are
described separately in the following sections. Both branches of the study include female
South Carolina residents ages 18-64 at diagnosis with stage 0-III or unstaged hormone
receptor-positive breast cancer; however, the individual women sampled in the
qualitative study may or may not have been included in the quantitative study. See
Appendix B for a table of variables that were used in the study.
The results of the quantitative and qualitative studies were used in conjunction to
better inform emerging interventions. By highlighting how ET usage rates have changed
since 2000 and which subgroups are in need of particular attention, interventions can
glean from past improvements and use resources more effectively. Demographic, clinical,
and pharmaceutical factors that are associated with longer ET usage duration can be
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highlighted and tested in interventions. The results generated from the quantitative
studies can be better validated and further explained by the qualitative study.
Understanding from the survivor perspective which modifiable factors could have the
greatest impact on the likelihood of ET continuation will be key to successful future
interventions.

Quantitative Research Design
The aim of the quantitative study is 1) to describe ET non-initiation, nonadherence, and duration by age, race, and temporal trend and 2) identify demographic,
clinical, and pharmaceutical factors that are associated with an individual’s ET usage
duration.
Data
South Carolina Central Cancer Registry (SCCCR) incidence data from 2000-2014
was used to identify the study sample and then linked with South Carolina Medicaid
prescription claims and administrative data from 2000 through September 2016.
Variables were obtained from the SCCCR data and Medicaid prescription claims and
administrative data as indicated in Appendix B. Non-initiation, non-adherence, and
duration outcomes were studied through the Medicaid prescription claims data.
The data were linked by South Carolina Department of Revenue and Fiscal
Affairs using probabilistic match by patient first name, last name, social security number,
and date of birth. Data was de-identified prior to release to the researchers. Clemson
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University (IRB2017-133) and South Carolina Department of Health and Environmental
Control Institutional Review Boards approved the study.
Sample
This retrospective cohort study included SC women ages 18-64 at diagnosis with
Stage 0-III or unstaged hormone receptor-positive breast cancer diagnosed between 2000
and 2014 (N=34,791). Breast cancer survivors who had SEER summary stage 7 cancer
(N=1,531), who did not have estrogen receptor-positive cancer (N=5,183), who had prior
cancer diagnoses (N=3,016), or whose cancer was identified through autopsy or death
certificate (N=72) were excluded. After linking with SC Medicaid prescription data,
breast cancer survivors who did not meet Medicaid eligibility inclusion criteria (i.e. no
prescription data; N=18,762 or dually enrolled in Medicare; N=2,397) were also
excluded. Those who were dually enrolled in Medicare were excluded because Medicare
prescription claims were not available and therefore, ET usage could not be reliably
tracked. After exclusions, there were 3,830 breast cancer survivors included in this study.
Dependent Variables
ET was defined as Tamoxifen or one of the following aromatase inhibitors:
Anastrozole/Arimidex, Letrozole/Femara, or Exemestane/Aromasin, which were
identified using National Drug Codes from the Medicaid prescription claims. Noninitiation was defined as not having any Medicaid prescription claims in the entire study
period (from 2000-2016). The non-initiation rate was calculated by dividing the number
of women who were ET non-initiators by the total number of eligible women (N=3,830).
Non-adherence was defined as an ET medication possession ratio of less than 80 percent,
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meaning that the pill supply covered less than 80 percent of the days from the first ET
prescription dispense date through the last (Hershman et al., 2010). Duration of ET usage
was calculated as the number of months between the first and last ET prescription
dispense date. The proportion of women taking ET for at least 5 years was calculated by
dividing the total number of women taking ET for at least 5 years by the total number of
women initiating ET. Non-adherence and duration were calculated using the date
dispensed and days supplied variables from the South Carolina Medicaid pharmacy
claims file.
Independent Variables
For Research Questions 1-2 (Aim 1), the independent variables were year of
breast cancer diagnosis, age at diagnosis (centered at mean), and race (0 = White, 1 =
African American).
For Research Question 3 (Aim 2), independent variables included the factors
hypothesized to be associated with ET usage duration based on literature review. The
following demographic, clinical, and pharmaceutical factors were examined:
• Demographic: race (White, African American, or other), age at diagnosis,
marital status (married/unmarried), and rural/urban residency status (2013 RuralUrban Continuum Codes)
• Clinical: SEER summary breast cancer stage, receipt of chemotherapy (yes/no),
and receipt of radiation therapy (yes/no)
• Pharmaceutical: Type of endocrine therapy (Tamoxifen, Anastrozole/Arimidex,
Exemestane/Aromasin, Letrozole/Femara, switched between aromatase inhibitors,
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switched between Tamoxifen and aromatase inhibitors), and filled alpha-agonist
hypertensives prescription (yes/no), filled antidepressants prescription (yes/no),
filled anticonvulsants prescription (yes/no), filled adrenals prescription (yes/no),
filled nonsteroidal anti-inflammatory agents prescription (yes/no), filled antiinflammatory agents prescription (yes/no), and filled vitamins prescription (B, C,
D, K, and/or multivitamin) (yes/no). The prescriptions were identified by
therapeutic class code and measured as ever having filled prescription during the
study period as evidenced by Medicaid claims.
Provider specialty data had a high number of missing values and therefore was not
included in the study.
Statistical Analysis: Aim 1
Demographic characteristics were compared between ET initiators and noninitiators using Chi-square tests. Relative risk was calculated for ET non-initiation for
each of the age/race subgroups, with white/age ≥ 50 years as the reference group.
ET non-adherence and usage duration analyses were conducted among women
who had filed at least one ET prescription claim through South Carolina Medicaid and
who were diagnosed between 2000 – 2012 (N=1,366). Women diagnosed in 2013 and
2014 were excluded due to the shortened follow-up time since prescription records were
only available through 2016. Chi-square tests were used to test for a difference in nonadherence rates among age/race subgroups (i.e. White/age < 50 years, African
American/age < 50 years, White/age ≥ 50 years, African American/age ≥ 50 years).
Relative risk of ET non-adherence was calculated for each of the age/race subgroups,
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with White/age ≥ 50 years as the reference group. Kruskal Wallis tests were used to test
for a difference in median duration of ET usage by age/race subgroups as previously
defined.
We also examined temporal trends in endocrine therapy (ET) non-initiation, nonadherence, and duration. Temporal trend was measured by calendar year of breast cancer
diagnosis. The objective was to study participants in groups by year of breast cancer
diagnosis since much of the information and motivation a woman receives for taking ET
in the long-term is provided in the initial conversation with a provider when the patient
receives the first ET prescription.
We used binary logistic regression to model whether an individual initiated ET or
not. We also used binary logistic regression to model whether an individual was adherent
to ET or not. We used ordinary least squares regression to estimate an individual’s ET
usage duration in months. In each of the three models, we controlled for the covariates
age (continuous variable centered at the mean) and race (0 = White, 1 = African
American).
The data was first examined visually and descriptive statistics were calculated.
The data did not meet the assumptions for linearity for any of the three outcomes, so nonlinear time trend models were chosen. Non-initiation rates resembled a cubic pattern, so
the time period was divided into three sub-periods to capture different trends occurring
during these three sub-periods. Non-adherence and duration seemed to generally increase
until the year 2006 and decrease thereafter, so time was divided into two sub-periods for
these analyses.
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To allow for nonlinear changes in ET non-initiation over time, we used a linear
spline with knots at 2004 and 2009. For non-initiation, we divided time into the periods
2000 – 2004, 2005 – 2009, and 2010 – 2014. To allow for changes in ET non-adherence
and duration observed before and after 2006, we used a linear spline with a knot at 2006.
For non-adherence and duration, we observed changes in the periods 2000 – 2006 and
2007 – 2012. Wald tests were used to determine whether the coefficients for the different
time periods were equivalent. Adjusted trends were examined by generating predicted
probabilities of ET non-initiation and non-adherence as well as average duration. Stata
14.2 was used for all analyses.
Statistical Analysis: Aim 2
Multiple linear regression models were built to explore the impact of
demographic, clinical, and pharmaceutical factors on ET usage duration in months (α =
0.05) for survivors diagnosed in 2000 – 2012 who filled at least one ET prescription
(N=1,399). First, a series of models was made by singularly entering each of the
independent variables with the dependent variable ET usage duration. Then, the
combined effect of the independent variables that were significantly associated with the
dependent variable was examined. Interactions terms were generated for each pair of
significant independent variables and entered as a block to test for significant association
with ET usage duration. The final model was generated by removing variables from the
model that were no longer significant when controlling for other factors and adding the
significant interaction terms. The final model included ET type; receipt of the following
concurrent prescriptions: adrenals, nonsteroidal anti-inflammatory agents, anti-
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inflammatory agents, and/or vitamins; and two-way interaction terms for ET
type/adrenals and anti-inflammatory agents/vitamins. StataMP 14.0 was used for all
analyses.

Qualitative Research Design
The qualitative study will aim to understand from the patient perspective which
modifiable factors have the greatest impact on the likelihood of ET continuation.
Recruitment
Breast cancer survivors were recruited through breast cancer support groups and
advocacy organizations and a local cancer survivorship institute. These included the
Greenville Health System Center for Integrative Oncology and Survivorship, the Komen
Foundation, and the South Carolina Witness Project as well as local breast cancer support
groups. Inclusion criteria for participation were female, English speaker, diagnosed with
Stage 0-III hormone receptor-positive breast cancer since 2000, completed breast cancer
treatment, and prescribed endocrine therapy between the ages of 18-64 years.
Recruitment for the fourth focus group heavily targeted women who had not initiated or
who had discontinued use of ET.
Patients meeting the study inclusion criteria were notified about the study during
clinic visits at the Center for Integrative Oncology and Survivorship. An e-mail invitation
was sent to a listserv of patients in the Greenville Health System Survivorship Registry, a
group of cancer survivors who had already consented to receive periodic notifications of
research studies for possible enrollment. In addition, the Komen Foundation, South
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Carolina Witness Project, and local breast cancer support groups used the recruitment
flyer (see APPENDIX C) to publicize the opportunity to participate in the study among
their members through meeting announcements, personal contact, e-mail, and social
media posts.
The recruitment flyer introduced potential participants to the project and invited
them to participate. Interested participants were directed to call a project team member at
an advertised phone number if willing to participate in a focus group. The project team
member receiving the call used a script for screening (see APPENDIX D) interested
participants and scheduled eligible participants for a focus group date and location. A
reminder call was made one week prior to the focus group, and a reminder e-mail was
sent one day prior to the group meeting. A Walmart gift card in the amount of $50 was
provided to each participant in return for their time and transportation costs.
Data Collection
The focus groups lasted approximately 1.5 hours each and were held in neutral,
private locations. All focus groups were conducted in English by two trained members of
the project staff. Participants received an informational letter at the beginning of the focus
group introducing them to the potential benefits and risks of the study. The moderators
used a focus group guide developed by the research team members with qualitative,
cancer-focused research experience after reviewing the existing literature to elicit
participants’ experiences with ET. The guide was driven by elements of the Health Belief
Model, specifically probing about perceived susceptibility to and seriousness of breast
cancer recurrence, perceived benefits and barriers to ET continuation, and cues to action
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that may support or encourage ET continuation. The various probes stimulated discussion
about specific events and experiences that shaped participants’ opinions and attitudes
regarding ET usage. The focus group guide is provided in APPENDIX E. Each focus
group was audio-recorded and then transcribed by a reputable medical transcription
service and verified by a member of the project staff. The group demographics were
obtained via a brief, anonymous survey (see APPENDIX F) that was administered prior
to the focus group. These demographics (e.g. age group, race, sex, ET type) were
collected for purposes of external validity.
Data Analysis
Data analysis was completed by three members of the research team with input
from a breast cancer survivors’ panel. The team used a grounded theory approach to
identify themes and an inductive narrative approach to data analysis (Bradley, Curry &
Dever, 2007; Kidd & Parshall, 2000; Thomas, 2006; Thorne, 2000). The team members
began by analyzing one of the focus group transcripts to create a codebook. The
codebook was expanded as the other three transcripts were analyzed. The analysis team
followed a process detailed by Miles and Huberman (Miles & Huberman, 1994), dividing
the coding duties so that each transcript was coded by at least two independent coders.
The team met during the coding process to address consensus, update the coding
structure, and revisit any previously coded text as needed. Codes were applied to
transcripts using Atlas.ti software Version 7.5.10 (Friese, 2013).
Themes emerged during a subsequent review and analysis of code based queries
using the Atlas.ti software. A priori codes drawn from the focus group guide, as informed
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by the Health Belief Model served as the organizing analysis framework. As new themes
emerged, the narrative was expanded. Two survivors who were not focus group
participants assisted with identifying themes and expanding the narrative. There were
fifteen final codes. Themes were examined by participant decision to continue or
discontinue ET, and quotations exemplifying each theme are provided in the results.
Patient Engagement Studio Involvement
The Meharry-Vanderbilt Community-Engaged Research Core began developing
the idea of a Community Engagement Studio in 2009, based on the idea of the Clinical
and Translational Research Studio (Joosten et al., 2015). While the Clinical and
Translational Research Studio convenes a panel of academic experts to provide projectspecific input to researchers, the Community Engagement Studio convenes a panel of
patients to consult with investigators on specific projects. These patients are viewed as
consultants as opposed to research subjects and are recruited and paid accordingly. The
novelty of the Community Engagement Studio as compared to other forms of patientcentered or community-based participatory research is that the investigators do not spend
time recruiting the stakeholders (Joosten et al., 2015). The Community Engagement
Studio staff members recruit and orient stakeholders, arrange and moderate the
discussion, take notes during the meeting, and prepare a written summary after the
meeting for the investigator. Through these means, investigator burden is minimized and
efficiency is maximized (Joosten et al., 2015).
A team of staff, faculty, and community partners from the Meharry-Vanderbilt
Community Engagement Studio developed a tool kit that other sites can use to replicate
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their Community Engagement Studio model. The Greenville Health System has recently
adapted the Meharry-Vanderbilt Community Engagement Studio model to form their
own Patient Engagement Studio. The qualitative branch of the proposed research study
was informed and guided by the input of a general Patient Engagement Studio and a
breast cancer specific Patient Engagement Studio, both from the Greenville Health
System.
A project team member presented the proposed study to the Greenville Health
System Patient Engagement Studio in January 2017 at the beginning of the study design
phase to ask for patient input regarding the qualitative study. This studio meets monthly
to review research and to provide feedback to researchers regarding their projects. Two
scientists with experience in quality initiatives, two academic physician clinicians from
the Greenville Health System, a Patient Experience expert, an Engagement Navigator,
five patient “experts,” and two breast cancer patients were present for the meeting. The
two breast cancer patients were recruited specifically for this studio meeting due to the
nature of the research topic.
The studio provided recommendations for patient recruitment including potential
concerns of Medicaid patients and the need to be sensitive to those during recruitment
planning, differences in older and younger patients and the need for clarifying the study
population and research questions accordingly as well as distrust or disinterest among
patients receiving a flyer through the mail and ways to overcome that barrier. Other
tangible suggestions included conducting the focus groups in a neutral location in the
community as opposed to a healthcare office, the appropriate amount to provide for
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incentives, and adding an anonymous demographic survey to the focus groups so that the
population could be generally described. Patients were intrigued by the project and its
potential significance.
In addition to this first interaction with the Greenville Health System Patient
Engagement Studio, a breast cancer specific Patient Engagement Studio was recruited by
the Greenville Health System Patient Engagement Studio director. This breast cancer
specific Patient Engagement Studio reviewed and provided input on the Health Belief
Model framework and the focus group guide in June 2017. Feedback from the Studio
included the following points, all of which were incorporated into the recruitment and
production of the focus groups:
• Be more neutral in the recruitment flyer language. For instance, “Taking
endocrine therapy is a ‘challenge’ for many women, rather than a using a negative
word such as “struggle.”
• In recruitment, be specific about the names of the medications since some
patients may not recognize the term “endocrine therapy.”
• Be more direct during the focus group introduction in telling women that if they
have shared a lot, we might call on someone else (and ask you to stop) so that
others can have a chance to share.
• When asking women to give the name they would like to be called by, don’t say
“or a pseudonym.” That “creeps people out” and makes them feel scared of why
this is so top secret. They’ve volunteered to come and want to share, so don’t
make it weird.
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• When asking about the initial conversation between the patient and “the” doctor,
be aware that the patient is not treated by one doctor but usually a team of
doctors. The patient has multiple appointments with multiple providers. In some
clinics, this means going room to room on the same day. In others, it means
driving to multiple offices over a period of time. Patients can receive mixed
messaging from multiple providers.
• It would be helpful to add a question about whether the patient had someone
who accompanied her to these appointments (like an advocate - someone who
could help listen and help in decision making).
• Rather than asking if the patient was “hesitant” to ask questions when talking
with the providers, ask if the patient felt “comfortable.”
• The patient may not understand the term “risk score,” so be more general and
discuss “risk of the cancer coming back.”
• Patients and providers should take mutual responsibility for the patient’s
healthcare. Rather than asking questions as if the provider was “doing something”
to the patient, ask in a more open way such as, “When you were talking about the
next steps, what came up? What did you and the provider discuss?” versus “Did
your doctor tell you…”
• Understand that worry is volatile. The patient’s amount of worry about the
cancer coming back is probably not the same all the time. Ask about a specific
point in time.
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• Be careful with how the conversation is directed in terms of future interventions.
Do not imply that the patients have made the wrong choice if they have chosen to
discontinue or not be adherent to the pill taking.
• Possibly use case scenarios to ask for intervention ideas, or possibly be more
general and discuss any medication in general. For instance, “Sometimes doctors
ask us to do things that are difficult/challenging. What are some strategies…?”
• It may be helpful to note participant body language during the focus groups.
•Be more general with the conversation. For instance, instead of asking a series of
pointed questions about the patient/provider interaction, say, “Tell us about your
first conversation with your provider about taking Tamoxifen. How did it make
you feel?”
• Eliminate the participant activities such as having patients come and mark their
level of worry on a chart. Participants will be more comfortable just responding
verbally instead.
Two members from this breast cancer specific Patient Engagement Studio helped
interpret the focus group results in December 2017. The patient perspective added much
value to the data analysis process. This meeting was especially helpful to hear ideas from
the patient perspective on how to practically and concisely organize the results. For
instance, Table 3.1 below presents the Cues to Action before and after the Patient
Engagement Studio meeting.
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Table 3.1 Cues to action before and after patient engagement studio involvement
Cues to Action BEFORE Patient
Engagement Studio Meeting to Analyze
Focus Group Results
 Doctor listens to patient, does not
judge, & does not minimize patient ET
experience
 Doctor open to helping lessen side
effects with holistic approaches and
switching ET meds
 Doctor engages with patient as patient
researches on her own and is part of
social media platforms & Medical
community engagement in social media
outlets
 Doctor initiates partnership with patient
in recommending what is best for
patient (patient desire to be treated as
an individual – “We are all different”)
 Doctor openly shares latest ET research
in patient-friendly manner
 Doctor is transparent about side effects
and shares upfront that there are
possible ways to alleviate potential side
effects
 Nutritionist gives personalized dietary
information based on medications and
conditions
 Concept of a “pharmacy home,”
especially for rural patients
 Nurse navigator available to discuss the
cost/benefit analysis of taking ET and
answer “weird questions”; even better
if nurse navigator initiates call
 Staff is friendly, caring, and prompt in
returning messages

Cues to Action AFTER Patient
Engagement Studio Meeting to Analyze
Focus Group Results
 Provider listens, does not judge, & does
not minimize the survivor’s unique,
individual ET experience
 Provider is transparent about side
effects and shares upfront that there are
possible ways, including holistic
options, to alleviate potential side
effects
 Provider engages with survivor as
survivor researches on her own and is
part of social media platforms; provider
shares latest ET research in patientfriendly manner
 Nurse navigator available to discuss the
risk vs. benefit analysis of taking ET
and answer “weird questions;” even
better if nurse navigator initiates call
 Concept of a “pharmacy home” where
survivor feels welcomed to ask
questions
 Nutritionist gives personalized dietary
information based on medications and
conditions
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CHAPTER FOUR
PAPER 1: “ENDOCRINE THERAPY USE IN THE 21ST CENTURY: TEMPORAL
TRENDS ILLUSTRATE OPPORTUNITIES FOR IMPROVEMENT FOR SOUTH
CAROLINA MEDICAID WOMEN”

Abstract
This study examines endocrine therapy (ET) non-initiation, non-adherence, and
duration by age, race, temporal trend for South Carolina Medicaid-enrolled women
diagnosed with hormone receptor-positive breast cancer between 2000 and 2014
(N=3,830).
Age, race, relative risk and median duration of ET use were compared. Temporal
trends in ET non-initiation, non-adherence, and duration were observed using linear and
logistic regression models, controlling for age and race.
Fifty three percent of women in the sample did not initiate ET, with highest noninitiation rates among African Americans and survivors under age 50. Of those who did
initiate ET, 42% were non-adherent with a median ET usage duration of 37 months.
Twenty one percent of initiators continued taking ET for five years or more. There was
no change in the odds of ET non-initiation from 2000 – 2004 (OR = 1.02, p = 0.67). The
odds of ET non-initiation decreased from 2005 – 2009 (OR = 0.81, p < 0.001) but then
increased from 2010 – 2014 (OR = 1.08, p = 0.002). There was no change in the odds of
ET non-adherence from 2000 – 2006 (OR = 1.02, p = 0.53), but from 2007 – 2012, the
odds of ET non-adherence decreased each year (OR = 0.93, p = 0.02). The average ET

39

usage duration was increasing from 2000 – 2006 (β = 2.74, p < 0.001) but decreasing
from 2006 – 2012 (β = -1.46, p < 0.001).
This study provides a realistic picture of the challenges associated with ET usage
among South Carolina Medicaid breast cancer patients. It particularly highlights small
improvements over time in ET usage rates, indicating more opportunities for
improvement in ET initiation, adherence, and duration among younger women of lower
socioeconomic status.
Introduction
With advances in breast cancer screening and treatment, the population of female
breast cancer survivors in the United States continues to grow and was estimated at over
3.5 million as of January 2016 [1]. This population is expected to total over 4.5 million
by 2026 [1]. An important issue for female breast cancer survivors is reducing the risk of
cancer recurrence. The risk of cancer recurrence can be influenced by many factors,
including the original cancer and the initial treatment.
Endocrine therapy (ET) has been used for decades as the primary means of
reducing the risk of breast cancer recurrence and improving disease-free survival in
women with hormone receptor-positive Stage 0-III disease [2]. However, non-initiation,
non-adherence, and discontinuation rates remain high [3, 4]. Numerous cross-sectional
studies have been published highlighting subgroups of women experiencing the highest
rates of ET non-initiation, non-adherence or discontinuation in certain populations, which
have often included women younger than age 50 or older than age 70, of African
American race, and/or of economically disadvantaged populations [5-11].
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Even though there has been greater attention given to ET in oncology literature
and practice [12, 13], a gap persists in the literature regarding how ET usage rates have
changed over time. There is an impetus to particularly explore longitudinal patterns
among populations that are known to experience special challenges related to cancer care,
especially younger and economically disadvantaged women [6, 8, 9, 14]. The purpose of
this study is to describe ET non-initiation, non-adherence, and duration by age, race, and
temporal trend for South Carolina Medicaid-enrolled women who had hormone receptorpositive breast cancer diagnosed between 2000 and 2014.

Methods
Data Source
South Carolina Central Cancer Registry incidence data from 2000-2014 were used
to identify the study sample and then linked with South Carolina Medicaid prescription
claims and administrative data from 2000 through 2016 [15]. The data were linked by
South Carolina Department of Revenue and Fiscal Affairs using probabilistic match by
patient first name, last name, Social Security number, and date of birth. Data was deidentified prior to release to the researchers. Clemson University (IRB2017-133) and
South Carolina Department of Health and Environmental Control Institutional Review
Boards approved the study.
Sample
This retrospective cohort study included South Carolina (SC) women ages 18-64
at diagnosis with Stage 0-III or unstaged hormone receptor-positive breast cancer
diagnosed between 2000 and 2014 (N=34,791). Breast cancer survivors who had SEER
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summary stage 7 cancer (N=1,531), who did not have estrogen receptor-positive cancer
(N=5,183), who had prior cancer diagnoses (N=3,016), or whose cancer was identified
through autopsy or death certificate (N=72) were excluded. After linking with SC
Medicaid prescription data, breast cancer survivors who did not meet Medicaid eligibility
inclusion criteria (i.e. no prescription data; N=18,762 or dually enrolled in Medicare;
N=2,397) were also excluded. Those who were dually enrolled in Medicare were
excluded because Medicare prescription claims were not available and therefore, ET
usage could not be reliably tracked. After exclusions, there were 3,830 breast cancer
survivors included in this study. (Figure 4.1)
Definition of Non-initiation, Non-adherence, and Duration of ET Usage
ET was defined as Tamoxifen or one of the following aromatase inhibitors:
Anastrozole/Arimidex, Letrozole/Femara, or Exemestane/Aromasin, which were
identified using National Drug Codes from the Medicaid prescription claims. Noninitiation was defined as not having any Medicaid prescription claims in the entire study
period (from 2000-2016). The non-initiation rate was calculated by dividing the number
of women who were ET non-initiators by the total number of eligible women (N=3,830).
Non-adherence was defined as an ET medication possession ratio of less than 80 percent,
meaning that the pill supply covered less than 80 percent of the days from the first ET
prescription dispense date through the last [16]. Duration of ET usage was calculated as
the number of months between the first and last ET prescription dispense date. The
proportion of women taking ET for at least 5 years was calculated by dividing the total
number of women taking ET for at least 5 years by the total number of women initiating
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ET. Non-adherence and duration were calculated using the date dispensed and days
supplied variables from the South Carolina Medicaid pharmacy claims file.
Statistical Analysis
Demographic characteristics were compared between ET initiators and noninitiators using Chi-square tests. Relative risk was calculated for ET non-initiation for
each of the age/race subgroups, with white/age ≥ 50 years as the reference group.
ET non-adherence and usage duration analyses were conducted among women
who had filed at least one ET prescription claim through South Carolina Medicaid and
who were diagnosed between 2000 – 2012 (N=1,366). Women diagnosed in 2013 and
2014 were excluded due to the shortened follow-up time since prescription records were
only available through 2016. Chi-square tests were used to test for a difference in nonadherence rates among age/race subgroups (i.e. White/age < 50 years, African
American/age < 50 years, White/age ≥ 50 years, African American/age ≥ 50 years).
Relative risk of ET non-adherence was calculated for each of the age/race subgroups,
with White/age ≥ 50 years as the reference group. Kruskal Wallis tests were used to test
for a difference in median duration of ET usage by age/race subgroups as previously
defined.
We also examined temporal trends in endocrine therapy (ET) non-initiation, nonadherence, and duration. Temporal trend was measured by calendar year of breast cancer
diagnosis. The objective was to study participants in groups by year of breast cancer
diagnosis since much of the information and motivation a woman receives for taking ET
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in the long-term is provided in the initial conversation with a provider when the patient
receives the first ET prescription.
We used binary logistic regression to model whether an individual initiated ET or
not. We also used binary logistic regression to model whether an individual was adherent
to ET or not. We used ordinary least squares regression to estimate an individual’s ET
usage duration in months. In each of the three models, we controlled for the covariates
age (continuous variable centered at the mean) and race (0 = White, 1 = African
American).
The data was first examined visually and descriptive statistics were calculated.
The data did not meet the assumptions for linearity for any of the three outcomes, so nonlinear time trend models were chosen. Non-initiation rates resembled a cubic pattern, so
the time period was divided into three sub-periods to capture different trends occurring
during these three sub-periods. Non-adherence and duration seemed to generally increase
until the year 2006 and decrease thereafter, so time was divided into two sub-periods for
these analyses.
To allow for nonlinear changes in ET non-initiation over time, we used a linear
spline with knots at 2004 and 2009. For non-initiation, we divided time into the periods
2000 – 2004, 2005 – 2009, and 2010 – 2014. To allow for changes in ET non-adherence
and duration observed before and after 2006, we used a linear spline with a knot at 2006.
For non-adherence and duration, we observed changes in the periods 2000 – 2006 and
2007 – 2012. Wald tests were used to determine whether the coefficients for the different
time periods were equivalent. Adjusted trends were examined by generating predicted
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probabilities of ET non-initiation and non-adherence as well as average duration. Stata
14.2 was used for all analyses.

Results
Initiation
There were 3,830 Medicaid-eligible women who had hormone receptor-positive
breast cancer diagnosed between 2000 and 2014 who met the inclusion criteria for this
analysis. Approximately half of these women (53%, N=2,030) did not fill an ET
prescription as evidenced by Medicaid prescription claims.
Demographic characteristics of ET initiators and non-initiators were examined.
(Table 4.1) The highest non-initiation rates were seen in African Americans (55% noninitiation) and survivors under age 50 (56% non-initiation). Compared to White women ≥
50, the relative risks for African Americans < 50, White women < 50 and African
American women ≥ 50 were 1.24 (95% CI: 1.14, 1.36), 1.23 (95% CI: 1.12, 1.34), and
1.16 (95% CI: 1.05, 1.28), respectively. Non-initiation rates and risk ratios by age/race
subgroups are presented in Table 4.2.
Non-Adherence
Among all initiators, 42% (N=755) of survivors were non-adherent. There was a
statistically significant difference in the non-adherence rates among the age/race
subgroups (χ2= 57.91, df = 3, p < 0.001). African American women younger than 50
years old had the highest non-adherence rates (55%) and were 1.67 (95% CI: [1.43,
1.95]) times as likely to be non-adherent to ET compared to the most adherent group (i.e.
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White women age 50 or older). Risk ratios for non-adherence by age/race subgroups are
presented in Table 4.3.
Duration
The median duration of ET usage from 2000 – 2012 was 37 months (Range: 0 –
184). Twenty-one percent of survivors (N=288) who initiated ET during 2000 – 2012
continued taking ET for five or more years. Five percent (N=90) only filled one ET
prescription and did not refill after the first prescription. A Kruskal Wallis test showed
there was no significant difference in median duration of ET usage by age/race subgroups
(χ2 = 1.12, df = 3, p = 0.77).
Temporal Trends
The non-initiation rates by year of diagnosis are presented in Table 4.4. We found
a significant difference in the ET non-initiation trends in the three time periods examined
(χ2(3) = 126.74, p < 0.001). There was no change in the odds of ET non-initiation from
2000 – 2004 (OR = 1.02, p = 0.67). The odds of ET non-initiation decreased from 2005 –
2009 (OR = 0.81, p < 0.001) but then increased from 2010 – 2014 (OR = 1.08, p =
0.002).
The non-adherence rates and median duration of ET usage by year of breast
cancer diagnosis are presented in Table 4.5. Results showed that there was a significant
difference in the ET non-adherence trends before and after 2006 (χ2(2) = 7.01, p = 0.03).
There was no change in the odds of ET non-adherence from 2000 – 2006 (OR = 1.02, p =
0.53), but from 2007 – 2012, the odds of ET non-adherence decreased each year (OR =
0.93, p = 0.02).

46

There was also a significant difference in the ET usage duration trends before and
after 2006 (F(2, 1361) = 15.51, p < 0.001). The average ET usage duration was
increasing from 2000 – 2006 (β = 2.74, p < 0.001) but decreasing from 2007 – 2012 (β =
-1.46, p < 0.001).
Figure 4.2 presents the adjusted average probabilities of ET non-initiation and
non-adherence by year of breast cancer diagnosis as well as the adjusted average ET
usage duration by year of breast cancer diagnosis.

Conclusion
This is the first study to use longitudinal data to examine trends in ET noninitiation, non-adherence, and duration among South Carolina Medicaid-enrolled women.
Our findings point to several opportunities for further investigation and possible
intervention. First, 53% of Medicaid enrollees never initiated treatment. This is of
concern for multiple reasons. Secondly, when examining the subgroups for possible
intervention to increase ET adherence, women under 50 years of age, and especially
African American women under age 50, demand particular attention. Thirdly, the odds
of ET non-initiation was increasing from 2010 – 2014 and the average duration of ET
usage was decreasing from 2007 – 2012.
There was, however, a significant decline in the odds of ET non-adherence from
2007 to 2012, and the odds of ET non-initiation had decreased previously in the period
from 2005 – 2009 with average duration increasing from 2000 - 2006. These positive
findings are encouraging given the recent attention touting the benefits of ET adherence
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for women [6]. Because the study spans more than a decade, this data offers one of the
first long-term assessments of these challenges. The opportunity is to build on the
modest positive improvements seen earlier in the past decade.
Those who initiated ET had a median ET usage duration of 37 months (Range: 0
– 184), with 21% of initiators continuing ET for five years or more. Given ASCO’s
recommendations since 2014 to increase ET usage to up to ten years and multiple trials
showing disease-free survival benefits for those who take ET for 5-10 years [12, 13, 1719], it is alarming that only one-fifth of initiators continued for five years or more and
that the temporal trends showed negative results for the most recent periods concerning
improvement in individual level ET initiation and duration.
We found that women under age 50 were less likely to be adherent to ET. These
findings are consistent with the literature on ET usage [8], which suggests that younger
women have unique considerations in their ET decision-making framework, including
fertility [20] and reluctance to believe ET was a necessary part of their breast cancer
treatment [21]. These explanatory factors are not fully understood and warrant further
research [22].
Some important limitations accompany this analysis. First, we assumed that if a
person was Medicaid-eligible and did not have a Medicaid pharmacy claim for ET, she
did not take ET, as there was no other way to document ET received through other
payment sources. Medicaid recipients do not typically have secondary payment sources
other than self-pay, so it is not anticipated that significant missed data resulted from this
limitation. Second, we assumed that if a person filled a prescription, then she took those
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pills. There was no way to account for whether the women actually took the medication.
Furthermore, our findings were based on data from the South Carolina Medicaid
population and may not be generalizable to other populations.
While promising that rates of non-initiation showed slight yet significant
decreasing trends and duration showed a slight yet significant increasing trend, these
results sound a call for greater improvements in ET usage rates among populations of low
socioeconomic status. More research is needed to decipher potential factors influencing
slight improvements seen since 2000 in order to capitalize on these efforts to further
reduce rates of non-initiation and non-adherence and increase duration in the future.
Moreover, longitudinal analyses among women with private insurance or Medicare are
warranted to compare changes in ET usage rates over time among these populations.
Additional analyses should also consider grouping participants by the year corresponding
to the middle or end of an individual’s ET duration period, where this study chose to
group participants by year of breast cancer diagnosis.
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Figures
Figure 4.1. Cohort selection criteria

Figure 4.2 Adjusted trends in South Carolina Medicaid breast cancer survivors’
endocrine therapy non-initiation, non-adherence, and duration by year of breast cancer
diagnosis
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Tables
Table 4.1 Demographic characteristics of South Carolina Medicaid breast cancer
survivor endocrine therapy initiators and non-initiators, 2000 – 2014
Initiators
(N=2,030)

Non-initiators
(N=1,800)

Race, %
White
50%
53%
African American
49%
45%
Age, %
< 50 years old
40%
47%
≥ 50 years old
60%
53%
Note: The statistical differences were tested using χ2 tests.

P-values
0.025

< 0.001

Table 4.2 Endocrine therapy non-initiation rates (%) and relative ratios (95% CI) by age
and race subgroups of South Carolina Medicaid breast cancer survivors
Age
Race

Rate
White
African American
Relative Risk
White
African American

< 50 Years
56%
57%

≥ 50 Years
46%
53%

1.23 (1.12, 1.34)
1.24 (1.14, 1.36)

1.00
1.16 (1.05, 1.28)

Table 4.3 Endocrine therapy non-adherence rates (%) and relative ratios (95% CI) by age
and race subgroups of South Carolina Medicaid breast cancer survivors
Age
Race

Rate
White
African American
Relative Risk
White
African American

53

< 50 Years
45%
55%

≥ 50 Years
33%
34%

1.36 (1.18, 1.63)
1.67 (1.43, 1.95)

1.00
1.04 (0.86, 1.27)

Table 4.4 Endocrine therapy non-initiation rates among South Carolina Medicaid breast
cancer survivors by year of diagnosis, 2000 – 2014
Year of Breast
Cancer
Diagnosis

White/age <
50 years
(N=1,093), %

2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2000-14

66.2
75.0
69.2
73.1
64.1
53.2
52.5
50.0
58.7
47.1
41.4
45.3
55.4
49.5
58.3
57.3

African
American/age
< 50 years
(N=1,034), %
69.2
69.4
68.1
63.0
71.1
64.7
50.0
49.2
53.7
43.2
46.2
50.7
52.5
54.5
54.3
57.3
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White/age ≥ 50
years (N=872),
%
63.4
40.0
61.0
73.5
64.9
60.0
43.5
41.9
52.5
28.3
32.8
31.1
41.9
42.0
46.0
48.2

African
American/age ≥
50 years
(N=757), %
61.5
65.9
73.2
66.7
74.4
57.1
74.3
56.8
50.0
38.9
38.9
48.1
47.3
37.9
39.5
55.4

All Women in
Sample
(N=3,830), %
65.3
64.0
68.2
69.2
67.3
58.3
53.4
49.0
53.4
40.7
40.3
42.6
49.5
46.0
50.1
54.5

Table 4.5 Demographics and endocrine therapy usage non-adherence and duration
patterns in South Carolina Medicaid breast cancer survivors by year of diagnosis, 2000 –
2014
Year of
Total
Diagnosisa No. in
Sampleb

No.
White,
age < 50
years

No.
White,
age ≥
50
years
15

No.
African
American,
age ≥ 50
years
20

Percent
Nonadherent
(N)

Median
Duration of
ET (range),
monthsb

22

No.
African
American,
age < 50
years
16

2000

74

46% (34)

77
77
74

14
20
18

22
29
27

24
16
13

15
11
16

47% (36)
47% (36)
50% (37)

2004

54

14

13

13

10

44%(24)

2005
2006

78
88

29
28

18
23

14
26

15
9

50% (39)
50% (44)

2007
2008
2009

103
96
162

27
26
45

33
25
42

25
19
38

16
23
33

47% (48)
47% (45)
42% (68)

20.5 (0 –
184)
22 (0 – 142)
30 (0 – 167)
23.5 (0 –
112)
21.5 (0 –
147)
34 (0 – 123)
49.5 (0 –
119)
46 (0 – 111)
39 (0 – 90)
46.5 (0 –
138)
41 (0 – 79)
45 (0 – 137)
39 (0 – 142)

2001
2002
2003

2010
173
51
42
43
33
42% (72)
2011
179
47
36
62
28
34% (61)
2012
164
41
38
54
29
38% (62)
a
Survivors diagnosed in 2013 and 2014 could only be followed for 48 and 36 months,
respectively.
b

Sample included all female Medicaid recipients ages 18-64 at diagnosis with Stage 0-III or
unstaged hormone receptor-positive breast cancer diagnosed between 2000 and 2014 who filled at
least one ET prescription. Survivors with prior cancer diagnoses, who were dually enrolled in
Medicare, or whose cancer was identified through autopsy or death certificate were excluded.
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CHAPTER FIVE
PAPER 2: “FACTORS ASSOCIATED WITH LONGER ENDOCRINE THERAPY
USE BY SOUTH CAROLINA MEDICAID-INSURED BREAST CANCER
SURVIVORS”

Abstract
Endocrine therapy (ET) discontinuation rates remain high, despite its use for
decades as the primary means of increasing disease free survival in women with hormone
receptor-positive Stage 0-III breast cancer. Research informing enhanced intervention
methods is needed as is research regarding the optimal timing of these interventions. The
objective of this study is to determine demographic, clinical, and pharmaceutical factors
that are associated with longer ET usage duration.
South Carolina Central Cancer Registry incidence data linked with South Carolina
Medicaid prescription claims and administrative data were used. The study included a
sample (N=1,399) of female South Carolina Medicaid recipients with hormone receptorpositive breast cancer diagnosed between 2000 and 2012 who filled at least one ET
prescription. A series of multiple regression models were built to explore the association
of demographic, clinical, and pharmaceutical factors with ET usage duration.
Multiple linear regression analysis showed that none of the demographic or
clinical factors tested were significantly associated with ET usage duration. However, the
type of ET taken as well as receipt of the prescriptions that could have been used to
alleviate side effects (adrenals, nonsteroidal anti-inflammatory agents, anti-inflammatory
agents, and vitamins) were significantly associated.
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Our study highlights the potential value of concurrent prescriptions for improving
ET usage duration, with an optimal intervention point before 14 months post ET
initiation. Further research is needed to test pharmacologic interventions that may
significantly increase ET duration as well as other non-pharmacologic strategies for side
effect management.

Introduction
Endocrine therapy (ET) has been used for decades as the primary means of
increasing disease free survival in women with hormone receptor-positive Stage 0-III
breast cancer, yet discontinuation rates remain high [1, 2]. Murphy et al. (2012)
conducted a systematic review to examine literature from 1998-2012 related to ET
adherence and continuation in routine clinical settings. The percentage of tamoxifen
users who discontinued treatment ranged from 15–20% in the first year of therapy to 31–
60% at the end of five years [3]. The percentage of aromatase inhibitor users who
discontinued treatment ranged from 5–25% during the first two years of therapy [3].
Studies examining both tamoxifen and aromatase inhibitor users showed discontinuation
rates between 32-73% by the end of five years of treatment [3].
Numerous studies have been conducted to examine factors that contribute toward
non-adherent, non-persistent ET use. The following subgroups have been highlighted as
at-risk: low socioeconomic status [4-6], low social support [3, 7-8], greater comorbidity
[7-8], greater drug cost [3, 7], greater side effects [3, 8], lack of provider communication
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regarding the importance of ET [3, 8], extremes of age [3, 8], and follow-up care with a
general practitioner versus a cancer specialist [3, 8].
As literature has established, the Medicaid population is at high risk for poor ET
usage [4-6]. Interventions to improve ET usage have been conducted in various
populations, but there is especially a lack of evidence of how to improve ET usage among
Medicaid recipients [9-12]. Qualitative studies reveal that side effects, primarily
menopausal symptoms and/or joint pain, emerge as the major barrier to continuing ET for
the recommended duration [13-17]. Tested interventions have focused on patient
education and side effect management, including elements such as educational materials,
phone or text message reminders, vaginal moisturizers, topical oil for joint pain, and cool
pad pillow toppers [9, 18-21]. Recent systematic reviews of interventions targeted at
improving ET usage showed no meaningful improvements over usual care, highlighting
the urgent need for more effective interventions [9, 21-22]. Medications have been
recommended to alleviate ET side effects, including alpha-agonist hypertensives,
antidepressants, anticonvulsants, adrenals, nonsteroidal anti-inflammatory agents, antiinflammatory agents, and vitamins [23-28]. While the most effective methods for
necessary intervention are still under development, there is also a gap in the literature
regarding the optimal timing for intervention. The aim of this study is to identify
demographic, clinical, and pharmaceutical factors that are associated with an individual’s
ET usage duration in hopes that these factors can better inform emerging interventions.
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Methods
Data Source
The study sample was identified using South Carolina Central Cancer Registry
incidence data from 2000-2012 linked with South Carolina Medicaid prescription claims
and administrative data from 2000 through 2016 [29]. Probabilistic match by patient first
name, last name, Social Security number, and date of birth was used for the linkage
performed by the South Carolina Department of Revenue and Fiscal Affairs. Data was
de-identified prior to release to the researchers. Clemson University and South Carolina
Department of Health and Environmental Control Institutional Review Boards approved
this study.
Sample
The study sample (N=1,399) included all female South Carolina Medicaid
recipients ages 18-64 at diagnosis with stage 0-III or unstaged hormone receptor-positive
breast cancer diagnosed between 2000 and 2012 and who filled at least one ET
prescription. Exclusion criteria were SEER summary stage 7 cancer, estrogen receptornegative cancers, prior cancer diagnoses, cancer identification through autopsy or death
certificate, and dual enrollment in Medicare (since Medicare prescription claim data was
not available).
Dependent Variable
ET included tamoxifen and the following aromatase inhibitors:
Anastrozole/Arimidex, Letrozole/Femara, or Exemestane/Aromasin. Drugs were
identified using therapeutic class and National Drug Codes from Medicaid prescription
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claims. ET usage duration was calculated as the number of months between the first and
last ET prescription dispense dates using the date dispensed and days supplied variables
from the South Carolina Medicaid pharmacy claims file. Participants were followed from
the time of their first ET prescription filled through 2016.
Independent Variables
Independent variables included the factors hypothesized to be associated with ET
usage duration based on literature review. The following demographic, clinical, and
pharmaceutical factors were examined:


Demographic: race (white, African American, or other), age at diagnosis, marital
status (married/unmarried), and rural/urban residency status (2013 Rural-Urban
Continuum Codes)



Clinical: SEER summary breast cancer stage, receipt of chemotherapy (yes/no),
and receipt of radiation therapy (yes/no)



Pharmaceutical: Type of endocrine therapy (Tamoxifen, Anastrozole/Arimidex,
Exemestane/Aromasin, Letrozole/Femara, switched between aromatase inhibitors,
switched between Tamoxifen and aromatase inhibitors), and filled alpha-agonist
hypertensives prescription (yes/no), filled antidepressants prescription (yes/no),
filled anticonvulsants prescription (yes/no), filled adrenals prescription (yes/no),
filled nonsteroidal anti-inflammatory agents prescription (yes/no), filled antiinflammatory agents prescription (yes/no), and filled vitamins prescription (B, C,
D, K, and/or multivitamin) (yes/no). The prescriptions were identified by
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therapeutic class code and measured as ever having filled prescription during the
study period as evidenced by Medicaid claims.
Provider specialty data had a high number of missing values and therefore was not
included in the study.
Statistical Analysis
Multiple linear regression models were built to explore the impact of
demographic, clinical, and pharmaceutical factors on ET usage duration in months (α =
0.05). First, a series of models was made by singularly entering each of the independent
variables with the dependent variable ET usage duration. Then, the combined effect of
the independent variables that were significantly associated with the dependent variable
was examined. Interactions terms were generated for each pair of significant independent
variables and entered as a block to test for significant association with ET usage duration.
The final model was generated by removing variables from the model that were no longer
significant when controlling for other factors and adding the significant interaction terms.
The final model included ET type; receipt of the following concurrent prescriptions:
adrenals, nonsteroidal anti-inflammatory agents, anti-inflammatory agents, and/or
vitamins; and ET type/adrenals and anti-inflammatory agents/vitamins interactions.
StataMP 14.0 was used for all analyses.

Results
The study sample consisted of 1,399 hormone receptor-positive cancer survivors.
Fifty-three percent of women in the study sample were white (N=744), and 44% were
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African American (N=622). The median age at diagnosis was 49 years (Range: 21 – 64).
Twenty-nine percent (N=376) were single, 36% (N=456) were married, and 16%
(N=210) were divorced. Following the 2013 Rural-Urban Continuum Codes for South
Carolina, 79% (N=1,101) of the women resided in metropolitan counties. The breakdown
by SEER summary breast cancer stage was as follows: Stage 0 (N=164, 12%), Stage 1
(N=576, 41%), Stage 2 (N=24, 2%), Stage 3 (N=530, 38%), Stage 4 (N=88, 6%), and
unknown (N=17, 1%). Fifty-three percent (N=743) of the sample had received
chemotherapy, and 44% (N=612) had received radiation therapy.
Forty-one percent (N=577) of the women were taking Tamoxifen, and 36% were
taking aromatase inhibitors (Anastrozole/Arimidex: N=199, 14%, Exemestane/Aromasin:
N=34, 2%, Letrozole/Femara: N=186, 13%, switched between different aromatase
inhibitors: N=91, 7%). Twenty-two percent (N=312) of the women switched between
Tamoxifen and aromatase inhibitors.
Eight percent (N=110) had filled a prescription for alpha-agonist hypertensives,
60% (N=838) had filled a prescription for antidepressants, 32% (N=447) had filled a
prescription for anticonvulsants, 60% (N=843) had filled a prescription for adrenals, 57%
(N=801) had filled a prescription for nonsteroidal anti-inflammatory agents, 28%
(N=386) had filled a prescription for anti-inflammatory agents, and 27% (N=379) had
filled a prescription for vitamins (B, C, D, K, and/or multivitamins).
Multiple linear regression analysis showed that none of the demographic
or clinical factors tested (race, age at diagnosis, marital status, and rural/urban status,
SEER summary breast cancer stage, receipt of chemotherapy, receipt of radiation
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therapy) were significantly associated with ET usage duration. When base models were
created with each of the pharmaceutical variables and ET usage duration as the dependent
variable, each of the pharmaceutical variables were significantly associated with ET
usage duration except Alpha-agonist hypertensives (β = -1.80, p = 0.51). The results are
shown in Table 5.1 as Models A – G.
Next, all of the pharmaceutical variables were included in a regression model with
ET usage duration as the dependent variable. See Table 5.1, Model H. The results showed
that receipt of antidepressants and anticonvulsants was no longer significantly associated
with ET usage duration when controlling for the other pharmaceutical variables. These
variables were removed from the model. Interaction terms were generated between each
pair of pharmaceutical variables and entered as a block in the model; however, only the
interactions between ET type/adrenals (β = -2.5, p < 0.001) and anti-inflammatory
agents/vitamins (β = -9.96, p = 0.04) were significant. The final model was developed
and included ET type; receipt of the following concurrent prescriptions: adrenals,
nonsteroidal anti-inflammatory agents, anti-inflammatory agents, and/or vitamins; and
anti-inflammatory agents/vitamins and ET type/adrenals interactions. See Table 5.2.

Conclusion
Key Results & Interpretation
Our study found that none of the demographic or clinical factors examined were
significantly associated with an individual’s ET usage duration. The sample’s
socioeconomic and age (<64) homogeneity possibly overwhelmed differences in race,
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marital status, or rural/urban residency status, or as other studies have shown, side effect
management may be more impactful than demographic or clinical aspects [13-17, 30].
Similarly, Friese et al. found that race, SEER stage, worry about recurrence, and
primary oncology provider were not significantly associated with ET usage in a
population of Los Angeles County and Detroit metropolitan area breast cancer survivors;
however, age and taking two or more medications weekly were significantly associated
with greater ET persistence [31]. Women ages 20-79 were included in the Friese et al.
study. [31]. Calip et al. also found that in a sample of 40,009 women, increasing
polypharmacy and pill burden were associated with greater ET adherence, but different
effects were found depending on the medication class [32]. For example, lipid-lowering
drugs and antihypertensives were associated with higher adherence, and opioidcontaining analgesics, anxiolytics/antipsychotics, antidepressants, and insulin therapy
were associated with lower adherence [32].
Our study highlights the association between ET usage duration with ET type and
with other prescriptions that were possibly prescribed for side effect management. The
final model included ET type and receipt of certain prescriptions, which can be used to
alleviate common side effects of Tamoxifen and aromatase inhibitors: adrenals,
nonsteroidal anti-inflammatory agents, anti-inflammatory agents, and vitamins.
The model showed that the average ET duration was 14 months for women
meeting the sample inclusion criteria, taking Tamoxifen, and who had not filled a
prescription for any of the following: adrenals, nonsteroidal anti-inflammatory agents,
anti-inflammatory agents, and/or vitamins. Taking Anastrozole/Arimidex significantly
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increased ET usage duration by an average of 12.2 months over the duration for
Tamoxifen, and taking Letrozole/Femara significantly increased duration by 8.9 months.
Women who switched between different aromatase inhibitors or between Tamoxifen and
aromatase inhibitors took ET for an average of 23.6 or 29.3 months longer, respectively,
than Tamoxifen-only users. Having the following prescriptions was also significantly
associated with increased ET duration: adrenals (+10.9 months), nonsteroidal antiinflammatory agents (+8.5 months), anti-inflammatory agents (+9.9 months), and
vitamins (+11.24 months). As shown by the interaction terms in Table 2, the results are
not additive for survivors taking adrenals in combination with Letrozole/Femara,
switching between aromatase inhibitors, or switching between Tamoxifen and aromatase
inhibitors; or for survivors taking anti-inflammatory agents with vitamins.
Study Strengths & Limitations
The literature contains many studies on subpopulations affected by low rates of
ET usage. This study helps fill a gap in the literature regarding factors positively
associated with ET usage duration among the socioeconomically disadvantaged that
could potentially be used to better emerging interventions. The most effective methods
for these necessary interventions are still under development, and there is a gap in the
literature regarding the optimal timing for intervention. This study identifies that
demographic and clinical factors were not associated with ET usage duration for this
population; however, ET type and having prescriptions for drugs commonly known to
alleviate side effects was significantly associated.
This analysis should be viewed as a hypothesis-generating study and can be used
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to further investigate the relationship between ET type and other prescriptions taken with
ET with ET usage duration. The variables significantly associated with ET usage duration
explain 23% of the variance in ET usage duration among the sample, so further
investigation is warranted to determine other associated factors. The purpose of the
additional prescriptions was unknown, so it is also not known if these prescriptions were
written to specifically alleviate side effects or for other purposes. Next steps would
include looking at the timing of side effect prescriptions and ET medications. Dosage and
usage patterns of other prescriptions were also not examined, only that the individual
filled at least one prescription for the medication during the study period. Furthermore,
over-the-counter NSAIDS or vitamins could not be accounted for due to the nature of
Medicaid prescription claims data.
Generalizability & Future Research
This study focused on South Carolina Medicaid recipients who were hormone
receptor-positive breast cancer survivors. The results of this study point to an effective
point of intervention before 14 months for ET initiators who meet the sample inclusion
criteria and that ET type and other prescriptions taken by survivors are more important
for increasing the length of ET duration than the demographic and clinical factors
examined. Further research is warranted to test these findings in other populations.
Further research is also needed to test pharmacologic intervention strategies associated
with longer ET duration in this study in addition to other non-pharmacologic
interventions among low income populations [33].
Interventions aimed at enhancing the ET experience for breast cancer survivors to
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increase disease free survival and quality of life are an immediate need. The results of
this study can be seen as an important first step at examining factors associated with
longer ET usage.
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Tables
Table 5.1 Multiple regression results for variables associated with endocrine therapy usage duration for the South Carolina
Medicaid population, 2000 - 2012 (models A – H)

Constant
Type of Endocrine Therapy
Anastrozle/Arimidex
Exemestane/Aromasin
Letrozole/Femara
Switched Between AIs
Switched Between AIs
& Tamoxifen
Antidepressants

A

B

C

D

E

F

G

H

30.00 (1.07)**

33.37
(1.15)**

35.06
(0.88)**

31.23
(1.15)**

30.11
(1.09)**

34.09
(0.84)**

34.86
(0.85)**

17.22
(1.52)**

8.77 (2.11)**
1.06 (4.53)
0.76 (2.17)
13.73 (2.90)**
24.96 (1.81)**

9.22 (2.01)**
4.31 (4.30)
1.35 (2.06)
12.65 (2.76)**
22.82 (1.73)**
7.62
(1.49)**

Anticonvulsants

0.75 (1.42)
8.69
(1.56)**

Adrenals

1.44 (1.49)
10.96
(1.48)**

Nonsteroidal antiinflammatory agents

5.18 (1.40)**
13.49
(1.44)**

Anti-inflammatory agents

8.22 (1.41)**
13.56
(1.61)**

Vitamins (A, B, C, D, E, K,
and/or multi)
R-squared
Adjusted R-squared
No. observations

0.13
0.13
1,399

0.02
0.02
1,399

0.02
0.02
1,399

0.04
0.04
1,399

0.06
0.06
1,399

0.05
0.05
1,399

7.58 (1.52)**
10.99
(1.63)**

8.41 (1.50)**

0.03
0.03
1,399

0.23
0.22
1,399

Standard errors are reported in parentheses; AI = Aromatase Inhibitor; *, ** indicates significance at the 95% and 99% level, respectively.
Type of Endocrine Therapy – Tamoxifen and non-receipt of medications through Medicaid were set as the reference groups for the models.
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Table 5.2 Multiple regression results for variables associated with endocrine therapy
usage duration for the South Carolina Medicaid population, 2000 - 2012 (final model)
Variables

Coefficient

Intercept
14.06
Endocrine Therapy Type – Anastrozole/Arimidex
12.20
Endocrine Therapy Type – Exemestane/Aromasin
4.63
Endocrine Therapy Type – Letrozole/Femara
8.88
1
Endocrine Therapy Type – Switched Between AIs
23.58
Endocrine Therapy Type – Switched Between
29.27
1
Tamoxifen & AIs
Receipt of Adrenals Prescription
10.90
Receipt of Nonsteroidal Anti-Inflammatory Agents
8.46
Prescription
Receipt of Anti-Inflammatory Agents Prescription
9.91
Receipt of Vitamins Prescription
11.24
Endocrine Therapy Type Adrenals
-5.32
Anastrozole/Arimidex
0.75
Exemestane/Aromasin
-13.66
Letrozole/Femara
1
-15.50
Switched Between AIs
-10.33
Switched Between Tamoxifen & AIs1
-7.06
Anti-Inflammatory Agents Vitamins
N=1,399; R2 = 0.23; Adj R2 = 0.22
Endocrine Therapy Type – Tamoxifen was set as the reference group
1
AIs=Aromatase Inhibitors
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Standard
Error
1.68
3.24
5.48
3.02
5.47
2.85

P-value

2.04
1.38

<0.001
<0.001

1.81
1.80

<0.001
<0.001

4.11
8.75
4.09
6.33
3.56
3.13

0.196
0.932
0.001
0.014
0.004
0.024

<0.001
<0.001
0.398
0.003
<0.001
<0.001

CHAPTER SIX
PAPER 3: “‘WALK A MILE IN MY SHOES’ – BREAST CANCER SURVIVORS’
PERSPECTIVES ON THE ENDOCRINE THERAPY EXPERIENCE”

Abstract
This study aims to understand, from the survivor perspective, modifiable factors
that have the greatest impact on the likelihood of endocrine therapy (ET) continuation.
Twenty-two hormone receptor-positive breast cancer survivors under age 64 who
had been prescribed ET since 2000 were recruited for participation in focus groups
conducted in four South Carolina locations. Qualitative data analysis was completed by a
three-member research team using an inductive narrative approach with input from a
breast cancer survivors’ panel at a local hospital. Themes were examined by participant
decision to continue or discontinue ET. Quotations exemplifying each theme are provided.
Participants’ feedback centered on a risk vs. benefit analysis unique to the
individual survivor. Main themes included the importance of an open, honest
patient/provider relationship and the need for personal information seeking and
affirmation in the decision to take ET. There was clear support for the utility of
multidisciplinary cancer care teams and incorporating integrative approaches.
This study highlights key elements that can be incorporated in interventions to
enhance the endocrine therapy experiences for breast cancer survivors, with the goal of
informing improvement in supportive therapy and care. The few studies that have
addressed currently used interventions to improve adherence showed little to no
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improvement over usual care. Research employing patient-centered perspectives is
imperative. Novel and practical patient-centered interventions in research exploring
openness in the patient/provider relationship, survivor information seeking practices,
multidisciplinary teams, and integrative approaches are needed.

Introduction
Following surgery, radiation therapy, and/or chemotherapy, a woman with Stage
I-III hormone receptor-positive breast cancer is typically prescribed endocrine therapy
(ET) for five years or longer [1, 2]. The purpose of ET is to reduce a woman’s risk of
breast cancer recurrence. Taking ET (Tamoxifen or an aromatase inhibitor) as prescribed
for five years can reduce the risk of recurrence by 40% and death by one-third [3].
Research and clinical practice confirm that rates of ET are quite low [4-6]. A
systematic review by Murphy et al. (2012) showed that discontinuation ranged from 31–
73%, measured at the end of 5 years of treatment [7]. ASCO and the National
Comprehensive Cancer Network currently recommend that women with Stage I-III breast
cancer take Tamoxifen, an aromatase inhibitor, or a combination of the two types of
endocrine therapies for up to ten years [1, 8-9].
Knowledge of the population affected by ET early discontinuation in South
Carolina (SC) is limited, as is knowledge of how to improve the ET experience for
survivors. The few studies that have addressed interventions showed limited to no
improvement over usual care and have included elements such as educational materials,
reminder notifications, acupuncture, and vaginal moisturizers [10-12]. This qualitative
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study aims to understand from the survivor perspective which modifiable factors could
have the greatest impact on the likelihood of ET continuation.

Methods
A qualitative study utilizing focus groups of breast cancer survivors was
conducted. Four focus groups were held between June and October 2017 in four SC
towns. This research was approved by the Greenville Health System and Clemson
University Institutional Review Boards.
In addition, this qualitative study has been informed and guided by the input of a
general Patient Engagement Studio and a breast cancer specific Patient Engagement
Studio. The Studio provided recommendations for patient recruitment, raised potential
survivor concerns, and offered valuable suggestions focus group guide revisions and
results interpretation.

Recruitment
Breast cancer survivors were recruited through breast cancer support groups and
advocacy organizations and a local cancer survivorship institute. Targeted inclusion
criteria were female, English speaker, diagnosed with Stage I-III hormone receptorpositive breast cancer since 2000, completed breast cancer treatment, and prescribed
endocrine therapy between the ages of 18-64 years.
Project staff contacted potential participants through flyer invitation. Interested
participants contacted a research project staff member as directed by the flyer, were
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screened by phone or e-mail, and were assigned to a focus group based on location.
Participants were incentivized with $50 gift cards.
Data Collection
The focus groups lasted approximately 1.5 hours each and were held in neutral,
private locations. All focus groups were conducted in English by two trained members of
the project staff. Participants received an informational letter at the beginning of the focus
group introducing them to the potential benefits and risks of the study. The moderators
used a focus group guide developed by the research team members with qualitative,
cancer-focused research experience after reviewing the existing literature to elicit
participants’ experiences with ET. The guide was driven by elements of the Health Belief
Model, specifically probing about perceived susceptibility to and seriousness of breast
cancer recurrence, perceived benefits and barriers to ET continuation, and cues to action
that may support or encourage ET continuation [13]. The various probes stimulated
discussion about specific events and experiences that shaped participants’ opinions and
attitudes regarding ET usage. (See “Focus Group Guide” in Supplementary Materials.)
Each focus group was audio-recorded and then transcribed by a reputable medical
transcription service and verified by a member of the project staff. The group
demographics were obtained via survey.
Data Analysis
Data analysis was completed by three members of the research team with input
from a breast cancer survivors’ panel. The team used a grounded theory approach to
identify themes and an inductive narrative approach to data analysis [14-17]. The team
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members began by analyzing one of the focus group transcripts to create a codebook.
The codebook was expanded as the other three transcripts were analyzed. The analysis
team followed a process detailed by Miles and Huberman [18], dividing the coding duties
so that each transcript was coded by at least two independent coders. The team met
during the coding process to address consensus, update the coding structure, and revisit
any previously coded text as needed. Codes were applied to transcripts using Atlas.ti
software Version 7.5.10 [19].
Themes emerged during a subsequent review and analysis of code based queries
using the Atlas.ti software. A priori codes drawn from the focus group guide, as informed
by the Health Belief Model served as the organizing analysis framework. As new themes
emerged, the narrative was expanded. Two survivors who were not focus group
participants assisted with identifying themes and expanding the narrative. There were
fifteen final codes. Themes were examined by participant decision to continue or
discontinue ET, and quotations exemplifying each theme are provided.

Results
There were 22 total participants. Participants were a median age of 52 when first
prescribed ET (Range: 37– 63 years). Sixty-four percent were Caucasian, 23% were
African American, and 14% were of other race. Participants varied by highest education
attained: 18% high school diploma, 14% associates’ degree, 41% bachelors’ degree, 18%
post-baccalaureate degree, and 9% preferred not to answer. Seventy-seven percent had
private insurance, 9% were on Medicaid, 5% were on Medicare, and insurance type was
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unknown for 9% of the group. Fifty percent were prescribed Tamoxifen, 41% were
prescribed aromatase inhibitors, and 9% switched between Tamoxifen and aromatase
inhibitors. Five participants (approximately 23%) had discontinued ET. Two of the 17
who continued ET said they had taken a break of at least six weeks before deciding to
continue again. Table 1 provides more detail on participants’ ET usage. (See Table 6.1.)
The Health Belief Model was chosen to summarize the survivors’ responses, as
the women’s perceived susceptibility to breast cancer recurring and perceived
seriousness/severity of that event influenced the perceived threat of breast cancer
recurrence, which influenced the likelihood of a survivor continuing endocrine therapy.
Informed by various sources, survivors’ perceptions of endocrine therapy’s benefits and
barriers also influenced the likelihood of a survivor continuing ET. (See Figure 6.1.) The
five main themes that emerged from the analysis are described below.
Risk vs. Benefit Analysis
Across the four focus groups, discussion centered on the perceived risks vs.
perceived benefits that respondents felt was unique to the individual and could not be
generalized by providers. Continuers and discontinuers alike had experienced many side
effects that affected quality of life and were the major barrier to continuing ET. These
included joint pain, bone pain, muscle aches, depression, weight gain, eye problems,
anger, personality changes, hot flashes, lack of energy, vaginal dryness, and painful sex.
Many women said that taking the medication made them feel “like a 90 year old.” Most
discontinuers made statements such as “I just couldn’t take this anymore” and decided to
focus on quality of life, believing that ET’s benefits did not outweigh its harms. Some

78

discontinuers said their decision was influenced by a low recurrence risk score given by a
healthcare provider. The majority of discontinuers expressed understanding of their risk
but were very keen to incorporate dietary changes and supplements to improve overall
health instead of taking ET. Continuers largely expressed that they were weathering the
ET experience, though difficult for most, primarily due to fear of recurrence and not
wanting to have “regrets.” See Table 6.2. This risk vs. benefit analysis did not occur at
one time point and the decision to continue was not permanent. Participants alluded to
often re-evaluating their reduction in quality of life due to ET vs. ET’s benefit in reducing
recurrence risk often through conversations with the provider, husband, or other survivor,
and/or seeking online information.
Patient/Provider Relationship
The patient/provider relationship carried great significance in a survivor’s
decision to continue or discontinue ET. Survivors valued a provider who transparently
provided information about the purpose, benefits, and side effects of ET and ways side
effects may be alleviated. There were mixed opinions among survivors as to how much
information was “enough” regarding side effects. Some participants wanted to know any
possibilities upfront saying they would rather be “forewarned,” whereas other survivors
said being given too much information upfront was frightening and overwhelming:
If I have one, then I don’t say, ‘Oh my gosh, what’s wrong here?’ Okay, that
might be a side effect from this because it’s a new medication I’m taking. It’s
kind of nice to be forewarned.
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All survivors agreed that they desired a provider who listened to their concerns
and was not judgmental in minimizing the side effects a survivor experienced. Survivors
often made remarks such as, “We know our bodies because we live in them” and wanted
to be heard by providers. A continuer related her experience with a supportive provider:
You can be totally blunt with him. And he just really wants to help do what’s best
for you, but he listens to your issues. He doesn’t minimize how you’re feeling.
Several discontinuers indicated that their providers still think the survivors are
taking ET, and the survivors were not planning to inform the providers otherwise,
agreeing that they did not want to have to “argue.” Continuers said they valued
supportive providers’ willingness to help alleviate side effects by switching ET
medications and/or offering integrative approaches such as exercise, dietary changes, and
herbs. Some continuers reported changing providers to find someone that could support
them in this way. Many continuers reported continuing ET simply because it was their
providers’ recommendation, and they trusted their providers.
Information Seeking
The term “research” repeatedly surfaced in all four of the focus groups and among
both continuers and discontinuers. Participants were probed regarding their information
seeking behaviors. All groups expressed an understanding for the need to be cautious
with online research:
You have to take it with a grain of salt. There are a lot of blogs out there that are
just really misinformed completely. And you have to read it sort of weigh it…with
your oncologist and sort of figure it out.
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Participants also appreciated their cancer clinic or provider supplying links to
reputable sources. In addition to specific sites mentioned (e.g. Mayo Clinic and
American Cancer Society), participants also expressed an affinity for joining either online
or in-person discussion groups of breast cancer patients and survivors, citing that the
groups had been a very supportive place to ask questions, seek advice, and be encouraged
by women who understood what they were going through. Some participants found
groups very comforting and what they described as the best source of information
because the information shared by other survivors is “experiential.” Still others expressed
a desire to be more private about their care and seek information only from medical
professionals.
Some participants related that their providers were dismissive when survivors
mentioned the topic of joining online communities or researching information on their
own. Providers cautioned the women that they should not become part of such
communities for fear of the survivors becoming misinformed, which was described by a
discontinuer as “insulting” and “frustrating.” One continuer related a more positive
experience of chatting with other survivors online and learning about a medication that
had helped alleviate hot flashes for a woman in another state. After sharing the woman’s
experience with her provider, the provider prescribed the medication, consequently
helping the woman and allowing her to continue ET.
Multidisciplinary Cancer Care Teams
There was clear support for the utility of multidisciplinary cancer care teams. The
roles of nurse navigator, rural pharmacist, and nutritionist were specifically highlighted.
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Survivors whose cancer clinics had a nurse navigator differed in their opinion on the role.
All agreed it was comforting to have the nurse navigator’s phone number in case “you
have one of those weird questions.” However, many said it would have been very helpful
for the nurse navigator to have made an introductory contact. One survivor summarized
her experience in deciding whether to take ET and how the nurse navigator could have
assisted:
I’m sure she could have helped me a great deal because I was panicking going,
do I do this, do I not do this, you know, talking into my head and I didn’t want to
really talk it out to everybody else, because I didn’t want to hear everybody else’s
opinion. You know, because their opinion may not be in my best interest, but
they’re just going on what other people did. I really wanted somebody
knowledgeable.
Many participants said that they did not have any regular contact with a
pharmacist; however, in the most rural focus group location, the local pharmacist was
highlighted and discussed as a key source of trusted information for the participants.
Participants related instances of asking the pharmacist questions, saying “They will take
the time to talk with you.” and “What a blessing to have her!” Establishing trusting
relationships with pharmacists and these other mentioned allied health professionals was
reported as beneficial to survivors.
Integrative Approaches
Both continuers and discontinuers overwhelmingly expressed a desire for more
integrative approaches to help alleviate the side effects of ET and improve overall health.
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Some described providers who were excellent in sharing these options with survivors,
whereas others were frustrated with the lack of assistance they were receiving from
providers in this area. Many survivors discussed trying dietary modifications such as
excluding soy, sugar, grapefruit, and meat or including more fruits and vegetables,
turmeric, Calcium, Vitamin B, Vitamin C, Vitamin D and lemon drops in addition to
lifestyle changes such as more physical activity, less stress, yoga, and mindfulness. A
participant summarized the resounding call for these options as follows:
What we feel with the medical establishment is all they know is drugs and they cut
people and they dope people. We hear all the time, and most people are
educating themselves, but there’s all kinds of other healthy, exercise, diet, all
those things that you can do. But medical providers don’t do a whole lot to help
you with that or point you in the right direction.
Some participants were survivors at cancer clinics that offered nutrition
counseling but were not pleased with the services, saying that the information they had
received was the “same old, same old.” Nutrition and dietary change was of great
interest. Participants expressed a desire for more individualized counseling rather than
rather than generalized, elementary nutrition information.

Conclusion
ET discontinuation rates remain high despite the use of ET for decades as the
primary means of reducing the risk of breast cancer recurrence in women with hormone
receptor-positive Stage I-III disease [3, 20]. Existing studies have examined variables
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associated with ET continuation and adherence or address patient reported barriers but
highlight a gap in understanding from the patient perspective which modifiable factors
could improve the ET experience for patients [21-24].
In our qualitative study, we found clear survivor support for an open, honest,
ongoing patient/provider relationship, support for personal information seeking and
affirmation for continual ET risk vs. benefit re-evaluation, and multidisciplinary cancer
care teams that can provide integrative approaches to supplement conventional care.
There were several issues raised regarding the risk vs. benefit analysis that participants
felt was unique to the individual and could not be generalized by providers. Participant
feedback provided clear support for patient-centered and individualized cancer care.
These findings were consistent with other qualitative studies conducted among
similar populations. Van Londen et al. reported that women view taking ET as something
necessary for their health but re-evaluate the decision to take ET due to unanticipated side
effects [25]. Discussing these side effects with providers, family, and others was difficult,
and women were dissatisfied overall with the side effect symptom management
information and strategies available [25]. In addition, Pellegrini et al. similarly found that
women shared the distress and tension they felt while taking Tamoxifen because of the
paradoxical situation that the drug’s purpose was to save life but it was causing their
youthful looks and femininity to diminish [26].
One strength of our study is that it provides unique comparisons between the
opinions and concerns of ET continuers and discontinuers. While novel and informative
for hypothesis generation, a major limitation of this study is that the findings cannot be
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generalized to all breast cancer survivors, since the majority of women in the sample
were in the 40 to 50’s age group, above the state’s average education level, and proactive
toward their health and wellness. There was repetition in themes, indicative of saturation,
so we believe the sample was large enough to capture the most important opinions and
concerns of SC breast cancer survivors taking ET.
The knowledge gained from these focus groups is critical to guide future
development of interventions aimed at increasing ET continuation in this population.
Most notably, researchers and clinicians must consider how to address survivor concerns
regarding a more open, honest, ongoing two-way discussion between survivors and their
providers. Consistent with other studies of breast cancer survivors’ preferences, our study
showed that it may be helpful to employ a shared decision making model as the standard
of care when approaching the concept of endocrine therapy continuation and
modification of breast cancer recurrence risk factors, as is already being implemented for
initial breast cancer diagnosis and treatment [27-29]. As recommended by Charles, Gafni,
and Whelan (1997), shared decision making includes that 1) both the physician and
patient are involved, 2) both parties share information, 3) that both parties take steps to
build a consensus about the preferred treatment, and 4) that an agreement is reached on
the treatment to implement [30].
Survivors expressed a strong desire to make their own decisions with information
and guidance from their providers, consistent with the findings of Wells et al. [31]. Some
survivors indicated they were not able to have honest conversations about ET with their
providers. Others alluded to feeling condemned when trying to raise the issue of side
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effects or information found online or from other women. In order for a shared decision
making model to be implemented more effectively, it may be useful to train breast cancer
survivors to more assertively communicate with their providers, as has been effective
with other patient populations [32]. Likewise, the principles and practice of shared
decision-making should continually be incorporated in medical education and oncology
residency training programs.
Another main topic in patient/provider communication centered on discussions of
patient information seeking. Our study showed that survivors whose doctors criticized or
dismissed the online information they presented were more likely to follow advice from
other sources or go against the doctor’s advice possibly due to this perceived dissonance.
Tan and Goonawardene (2017) conducted a systematic review of Internet Health
Information Seeking and the Patient-Physician Relationship [33]. Similar to accounts
reported by some of the survivors in our study, this systematic review showed that some
survivors felt physicians avoided online information-related dialogues in order to reclaim
the traditional, authoritarian consultation model. Tan and Goonawardene affirm the
importance of allowing or encouraging survivors to discuss their online information
searches with physicians [33]. Their findings showed that survivors mainly used the
internet to be actively involved in decision making related to their health (i.e. preparing
for visits, asking better questions, better understanding information from physicians) but
still very much trusted their physicians and valued their consultations. This finding offers
a specific opportunity to provide patient centered care: provider’s recognition of a
patient’s efforts in the self-education process.

86

The systematic review findings showed these information seeking behaviors
actually empowered survivors to play a more active role in their disease management, to
become more effective in understanding and communicating with their physicians, and to
be more confident in and comfortable with their physicians’ advice. In addition, as Falisi
et al. (2017) reported in a systematic review of breast cancer survivors’ use of social
media, more study is needed to better understand social media engagement and content to
psychosocial, behavioral, and physical health outcomes and how best to leverage social
media to meet these needs [34].
The utility of multidisciplinary oncology teams that can incorporate integrative
approaches was highlighted in the focus groups. Some survivors had benefitted from care
by such teams while others had not. Multidisciplinary cancer care can be defined as a
“deliberately designed system that creates a common communication platform among
different providers of cancer care, enabling complex decision making and resulting in a
tailored individual management plan” [35]. The need for multidisciplinary care arose
from survivors feeling overwhelmed and confused after being transferred between
clinicians at various stages of diagnosis and treatment without an integrated approach
[36]. While existing multidisciplinary teams may typically be physician-led, our study
shows that it may be helpful to also include allied health professionals such as
pharmacists, nurse navigators, and nutritionists who may be working directly with the
patient over the course of five to ten years and can provide more individual counsel and
information related to integrative approaches as survivors continually re-evaluate the
decision of whether to continue ET [37]. Incorporating these individuals as part of the
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care team may also help improve the continuity of care, especially throughout the cancer
survivorship journey. Multidisciplinary teams that include allied health professionals and
nurse navigators align with the transition to a more patient-centered approach in cancer
care, in which increasing emphasis is placed on a survivor’s overall well-being and
quality of life, and survivorship [38-39].
As breast cancer survivors become an increasingly larger population, there is
imminent need for novel patient-centered interventions to enhance the ET experience.
This research and other patient-centered approaches are increasingly valuable in
providing insight into survivor care needs and perceptions, with a goal of ensuring that
cancer survivors have an opportunity for the most comprehensive and highest quality
cancer care possible.
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Figures
Figure 6.1 Health belief model for endocrine therapy usage to reduce risk of breast
cancer recurrence among low income South Carolina breast cancer survivors ages 18-64
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Tables
Table 6.1 Participant endocrine therapy usage characteristics (N=22)
Frequency (%)
Breast Cancer Stage at Diagnosis
0*
I
II
III
IV*
Type of Endocrine Therapy
Tamoxifen
Aromatase Inhibitor
Switched from Tamoxifen to Aromatase Inhibitor
Endocrine Therapy Continuation
Plans to Continue Endocrine Therapy for Recommended
Duration
Declined or Discontinued Endocrine Therapy

1 (5%)
10 (45%)
6 (27%)
4 (18%)
1 (5%)
11 (50%)
9 (41%)
2 (9%)
17 (77%)
5 (23%)
Median (Range)

Years on Tamoxifen
All Participants
2.5 (0 – 5)
Participants who Plan to Continue
3.7 (1.5 – 6)
Participants who Declined or Discontinued
0 (0 – 0.8)
Years on Aromatase Inhibitor
All Participants
2 (0 – 10)
Participants who Plan to Continue
3.3 (1-10)
Participants who Declined or Discontinued
0.6 (0 – 0.1)
*While Stage I-III was the target group for recruitment, one participant was Stage 0, and
one participant was Stage IV.
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Table 6.2 Sample quotes exemplifying participant perceptions regarding susceptibility
and severity of breast cancer recurrence and motivation for continuing or discontinuing
endocrine therapy
Continuer
 I feel like if it comes back it’s not
because I’m not doing everything I
was supposed to do.”
 “You feel like an 80-year-old woman
in the mornings sometimes, but I
have to have a security blanket.”
 “It’s bones and joints and all that, but
I just feel like I want to do everything
that I can because if it were to come
back, I am a guilty person…I should
have done this or I should have done
that. This way, if it does come back,
okay, I’ve done everything I can and
it’s in God’s hands.”
 “There really aren’t alternatives…I
want to be here. I’ve got little kids; I
will do it.”
 “My mom regretted not doing
treatment.”
 “Many went before us young.”
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Discontinuer
 “I don’t have any family history of
breast cancer, so it wasn’t something
that I was worried about as far as a risk
factor.”
 “If cancer’s gonna take me out, then let
cancer take me out. I’m not doing these
drugs. I don’t like to take drugs. I took
it a couple of days and it just made me
feel so bad until I decided this is not it.
If the Lord is ready for me, I’m going
home, but in the meantime, I was
telling my story. Letting other people
know, because folks were just afraid of
cancer.”
 “My doctors says without anything, the
difference is 3%. So, at my highest, it
would be like 16% recurrence. And I
said you know, I’m just at a point in
my life where I’m not worried about
getting cancer again. I’m not worried
about my body. My quality of life is
more important than what this could
offer.”

CHAPTER SEVEN
DISCUSSION

Overview of Study Findings and Strengths
This dissertation work had three major aims: 1) To describe ET non-initiation,
non-adherence, and duration by age, race, and temporal trend, 2) To identify demographic,
clinical, and pharmaceutical factors that are associated with an individual’s ET usage
duration, and 3) To understand from the survivor perspective which modifiable factors
could have the greatest impact on the likelihood of ET continuation. These aims were
achieved by a convergent parallel mixed methods research study. The answers to each of
the research questions are summarized Table 7.1.
Table 7.1 Summary of research aims, questions, hypotheses, and results
Research Question

Hypothesis

Results

AIM #1 To describe ET non-initiation, non-adherence, and duration by age, race, and
temporal trend
#1 How do rates of ET ET non-initiation, non- 53% of Medicaid enrollees never initiated
non-initiation, nonadherence, and
treatment. 21% of initiators continued ET
adherence, and
duration rates are
for five years or more, with a mean and
duration vary by age
worse among younger median of 37 months. African American
and race?
women and women of women under age 50 had the lowest rates of
African American
non-initiation and non-adherence. There was
race.
no significant difference in median duration
of ET usage by age/race subgroups
#2 How have rates of
There has been no
There was a significant decline in the odds
ET non-initiation, non- change over the study
of ET non-initiation from 2005 – 2009 but a
adherence, and
period in ET nonsignificant increase from 2010 – 2014. Nonduration changed
initiation, nonadherence decreased from 2007 – 2012.
during the study
adherence, and
Average duration of ET usage increased
period?
duration.
from 2000 – 2006 but decreased from 2007
– 2012.
AIM #2 To identify demographic, clinical, and pharmaceutical factors that are associated
with an individual’s ET usage duration
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#3 Which
demographic, clinical,
and pharmaceutical
factors are associated
with an individual’s
ET usage duration?

Women taking
None of the demographic or clinical factors
Tamoxifen will have
examined were significantly associated with
lower ET usage
an individual’s ET usage duration. The final
duration than women
model showed the following were
taking aromatase
significantly associated with longer ET
inhibitors. Filling
usage duration: type of ET and receipt of
prescriptions for drugs prescription for the following medications:
known to alleviate side adrenals, nonsteroidal anti-inflammatory
effects will increase
agents, anti-inflammatory agents, and
ET usage duration.
vitamins.
AIM #3 To understand from the survivor perspective which modifiable factors could have the
greatest impact on the likelihood of ET continuation.
#4 What are women’s’ Women’s
Continuers “just want to live” and are
perceptions regarding
susceptibility to breast fearful of regret/guilt if cancer recurs
susceptibility/severity cancer recurrence will
of breast cancer
be influenced by
Discontinuers emphasize importance of
recurrence?
provider-patient
quality of life; cite low risk score, no family
communication.
history, and/or not afraid of cancer or death
Women will perceive
recurrence as severe
but also be influenced
by short-term quality
of life preferences.
#5 What are the
Side effects will
Benefits: Understanding that endocrine
perceived
emerge as a major
therapy reduces estrogen levels which feed
benefits/barriers to ET perceived barrier to ET ER+ breast cancer
continuation?
continuation.
Barriers: Side effects, drugs are
toxic/harmful
#6 What are the cues
Provider-patient
 Provider listens, does not judge, & does
to action that
communication will
not minimize the survivor’s unique,
encourage and support play a key role in
individual ET experience
ET continuation?
supporting ET
 Provider is transparent about side effects
continuation.
and shares upfront that there are possible
ways, including holistic options, to
alleviate potential side effects
 Provider engages with survivor as
survivor researches on her own and is
part of social media platforms; provider
shares latest ET research in patientfriendly manner
 Nurse navigator available to discuss the
risk vs. benefit analysis of taking ET and
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answer “weird questions;” even better if
nurse navigator initiates call
Concept of a “pharmacy home” where
survivor feels welcomed to ask
questions
Nutritionist gives personalized dietary
information based on medications and
conditions

This is the first study to use longitudinal data to examine trends in ET noninitiation, non-adherence, and duration among South Carolina Medicaid-enrolled women.
Our findings point to several opportunities for further investigation and possible
intervention.

First, 53% of Medicaid enrollees never initiated treatment. This is of

concern for multiple reasons. Secondly, when examining the subgroups for possible
intervention to increase ET adherence, women under 50 years of age, and especially
African American women under age 50, demand particular attention. Thirdly, the odds of
ET non-initiation was increasing from 2010 – 2014 and the average duration of ET usage
was decreasing from 2007 – 2012.
There was, however, a significant decline in the odds of ET non-adherence from
2007 to 2012, and the odds of ET non-initiation had decreased previously in the period
from 2005 – 2009 with average duration increasing from 2000 - 2006. These positive
findings are encouraging given the recent attention touting the benefits of ET adherence
for women (Hershman et al., 2011). Because the study spans more than a decade, this data
offers one of the first long-term assessments of these challenges. The opportunity is to
build on the modest positive improvements seen earlier in the past decade.
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Those who initiated ET had a median ET usage duration of 37 months (Range: 0 –
184), with 21% of initiators continuing ET for five years or more. Given ASCO’s
recommendations since 2014 to increase ET usage to up to ten years and multiple trials
showing disease-free survival benefits for those who take ET for 5-10 years (Helwick,
2016; Goodman, 2017; Burstein et al., 2014; “ASCO Guideline Update,” 2014;
“Hormonal Therapy for Early-Stage,” 2016), it is alarming that only one-fifth of initiators
continued for five years or more and that the temporal trends showed negative results for
the most recent periods concerning improvement in individual level ET initiation and
duration.
We found that women under age 50 were less likely to be adherent to ET. These
findings are consistent with the literature on ET usage (Murphy et al., 2012), which
suggests that younger women have unique considerations in their ET decision-making
framework, including fertility (Rosenberg & Partridge, 2015) and reluctance to believe ET
was a necessary part of their breast cancer treatment (Walker et al., 2016). These
explanatory factors are not fully understood and warrant further research (Wassermann et
al., 2017).
Our study also found that none of the demographic or clinical factors examined
were significantly associated with an individual’s ET usage duration. The sample’s
socioeconomic and age (<64) homogeneity possibly overwhelmed differences in race,
marital status, or rural/urban residency status, or as other studies have shown, side effect
management may be more impactful than demographic or clinical aspects (Wagner et al.,

98

2018; Paul, 2011; Bluethmann et al., 2017; Wheeler et al., 2016; Wells et al., 2016; Felder
et al., 2016).
Our study highlights the association between ET usage duration with ET type and
with other prescriptions that were possibly prescribed for side effect management. The
final model included ET type and receipt of certain prescriptions, which can be used to
alleviate common side effects of Tamoxifen and aromatase inhibitors: adrenals,
nonsteroidal anti-inflammatory agents, anti-inflammatory agents, and vitamins.
The literature contains many studies on subpopulations affected by low rates of ET
usage. This study helps fill a gap in the literature regarding factors positively associated
with ET usage duration among the socioeconomically disadvantaged that could potentially
be used to better emerging interventions. The most effective methods for these necessary
interventions are still under development, and there is a gap in the literature regarding the
optimal timing for intervention. This study identifies that demographic and clinical factors
were not associated with ET usage duration for this population; however, ET type and
having prescriptions for drugs commonly known to alleviate side effects was significantly
associated.
In our qualitative study, we found clear survivor support for an open, honest,
ongoing patient/provider relationship, support for personal information seeking and
affirmation for continual ET risk vs. benefit re-evaluation, and multidisciplinary cancer
care teams that can provide integrative approaches to supplement conventional care. There
were several issues raised regarding the risk vs. benefit analysis that participants felt was
unique to the individual and could not be generalized by providers. Participant feedback
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provided clear support for patient-centered and individualized cancer care. A major
strength of the qualitative study is that it provides unique comparisons between the
opinions and concerns of ET continuers and discontinuers.

Limitations
Some important limitations accompany this analysis. First, we assumed that if a
person was Medicaid-eligible and did not have a Medicaid pharmacy claim for ET, she
did not take ET, as there was no other way to document ET received through other
payment sources. Medicaid recipients do not typically have secondary payment sources
other than self-pay, so it is not anticipated that significant missed data resulted from this
limitation. Second, we assumed that if a person filled a prescription, then she took those
pills. There was no way to account for whether the women actually took the medication.
Furthermore, our findings were based on data from the South Carolina Medicaid
population and may not be generalizable to other populations.
This study should be viewed as a hypothesis-generating study and can be used to
further investigate the relationship between ET type and other prescriptions taken with
ET with ET usage duration. The variables significantly associated with ET usage duration
explain 23% of the variance in ET usage duration among the sample, so further
investigation is warranted to determine other associated factors. The purpose of the
additional prescriptions was unknown, so it is also not known if these prescriptions were
written to specifically alleviate side effects or for other purposes.
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While novel and informative for hypothesis generation, a major limitation of the
qualitative portion of this study is that the findings cannot be generalized to all breast
cancer survivors, since the majority of women in the sample were in the 40 to 50’s age
group, above the state’s average education level, and proactive toward their health and
wellness. There was repetition in themes, indicative of saturation, so we believe the
sample was large enough to capture the most important opinions and concerns of SC
breast cancer survivors taking ET.

Future Work
While promising that rates of non-initiation showed slight yet significant
decreasing trends and duration showed a slight yet significant increasing trend, these
results sound a call for greater improvements in ET usage rates among populations of low
socioeconomic status. More research is needed to decipher potential factors influencing
slight improvements seen since 2000 in order to capitalize on these efforts to further
reduce rates of non-initiation and non-adherence and increase duration in the future.
Moreover, longitudinal analyses among women with private insurance or Medicare are
warranted to compare changes in ET usage rates over time among these populations.
Additional analyses should also consider grouping participants by the year corresponding
to the middle or end of an individual’s ET duration period, where this study chose to
group participants by year of breast cancer diagnosis.
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Next steps also include looking at the timing of side effect prescriptions and ET
medications. Dosage and usage patterns of other prescriptions were also not examined,
only that the individual filled at least one prescription for the medication during the study
period. Furthermore, over-the-counter NSAIDS or vitamins could not be accounted for
due to the nature of Medicaid prescription claims data.
The results of this study point to an effective point of intervention before 14
months for ET initiators who meet the sample inclusion criteria and that ET type and
other prescriptions taken by survivors are more important for increasing the length of ET
duration than the demographic and clinical factors examined.

Further research is

warranted to test these findings in other populations. Further research is also needed to
test pharmacologic intervention strategies associated with longer ET duration in this
study in addition to other non-pharmacologic interventions among low income
populations (David & Fallowfield, 2008).
The knowledge gained from the focus groups is critical to guide future
development of interventions aimed at increasing ET continuation in this population.
Most notably, researchers and clinicians must consider how to address survivor concerns
regarding a more open, honest, ongoing two-way discussion between survivors and their
providers. Consistent with other studies of breast cancer survivors’ preferences, our study
showed that it may be helpful to employ a shared decision making model as the standard
of care when approaching the concept of endocrine therapy continuation and
modification of breast cancer recurrence risk factors, as is already being implemented for
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initial breast cancer diagnosis and treatment (Mahmoodi & Sargeant, 2017; Mandelblatt
et al., 2006; Charles, Gafni, & Whelan, 2004).
Survivors expressed a strong desire to make their own decisions with information
and guidance from their providers, consistent with the findings of Wells et al. (2016).
Some survivors indicated they were not able to have honest conversations about ET with
their providers. Others alluded to feeling condemned when trying to raise the issue of
side effects or information found online or from other women. In order for a shared
decision making model to be implemented more effectively, it may be useful to train
breast cancer survivors to more assertively communicate with their providers, as has been
effective with other patient populations (Lee et al., 2013). Likewise, the principles and
practice of shared decision-making should continually be incorporated in medical
education and oncology residency training programs.
Another main topic in patient/provider communication centered on discussions of
patient information seeking. Our study showed that survivors whose doctors criticized or
dismissed the online information they presented were more likely to follow advice from
other sources or go against the doctor’s advice possibly due to this perceived dissonance.
Tan and Goonawardene (2017) conducted a systematic review of Internet Health
Information Seeking and the Patient-Physician Relationship. Similar to accounts reported
by some of the survivors in our study, this systematic review showed that some survivors
felt physicians avoided online information-related dialogues in order to reclaim the
traditional, authoritarian consultation model. Tan and Goonawardene affirm the
importance of allowing or encouraging survivors to discuss their online information
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searches with physicians. Their findings showed that survivors mainly used the internet
to be actively involved in decision making related to their health (i.e. preparing for visits,
asking better questions, better understanding information from physicians) but still very
much trusted their physicians and valued their consultations. This finding offers a
specific opportunity to provide patient centered care: provider’s recognition of a patient’s
efforts in the self-education process.
The utility of multidisciplinary oncology teams that can incorporate integrative
approaches was highlighted in the focus groups. Some survivors had benefitted from care
by such teams while others had not. Multidisciplinary cancer care can be defined as a
“deliberately designed system that creates a common communication platform among
different providers of cancer care, enabling complex decision making and resulting in a
tailored individual management plan” (Jacobson, 2010). The need for multidisciplinary
care arose from survivors feeling overwhelmed and confused after being transferred
between clinicians at various stages of diagnosis and treatment without an integrated
approach (Jnr, 2011). While existing multidisciplinary teams may typically be physicianled, our study shows that it may be helpful to also include allied health professionals such
as pharmacists, nurse navigators, and nutritionists who may be working directly with the
patient over the course of five to ten years and can provide more individual counsel and
information related to integrative approaches as survivors continually re-evaluate the
decision of whether to continue ET (Taplin et al., 2016). Incorporating these individuals
as part of the care team may also help improve the continuity of care, especially
throughout the cancer survivorship journey. Multidisciplinary teams that include allied
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health professionals and nurse navigators align with the transition to a more patientcentered approach in cancer care, in which increasing emphasis is placed on a survivor’s
overall well-being and quality of life, and survivorship (Borras et al., 2014; Lee
Mortensen et al., 2017).
As breast cancer survivors become an increasingly larger population, there is
imminent need for novel patient-centered interventions to enhance the ET experience.
This research and other patient-centered approaches are increasingly valuable in
providing insight into survivor care needs and perceptions, with a goal of ensuring that
cancer survivors have an opportunity for the most comprehensive and highest quality
cancer care possible. Interventions aimed at enhancing the ET experience for breast
cancer survivors to increase disease free survival and quality of life are an immediate
need. The results of this study can be seen as an important first step at examining factors
associated with longer ET usage.
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Appendix A
Health Belief Model for Endocrine Therapy Usage to Reduce Risk of Breast Cancer Recurrence
among South Carolina Breast Cancer Survivors Ages 18-64 at Diagnosis
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Appendix B
Table of Variables
Variables

Data Source
QUANTITATIVE STUDY
Sex, age at diagnosis, SEER summary breast
SC Central Cancer
cancer stage, month/year of diagnosis
Registry
Cancer recurrence date, type of reporting
SC Central Cancer
source (to distinguish autopsy or death
Registry
certificate), vital status
Dual enrollment in Medicare
National Drug Code and drug name, date
dispensed
Medicaid eligibility & ineligibility dates
Quantity, number of this refill & days
supplied
Demographic: race
Demographic: rural/urban residency status,
county of residence, marital status
Demographic: marital status

SC Medicaid Pharmacy
File
SC Medicaid Recipient
File
SC Medicaid Pharmacy
File
SC Central Cancer
Registry
SC Central Cancer
Registry
SC Medicaid Recipient
File
SC Central Cancer
Registry
SC Medicaid Pharmacy
File

Clinical: receipt of other treatments (i.e.
chemotherapy, radiation therapy, surgery)
Pharmaceutical: type of endocrine therapy,
pharmacy ownership, and filled prescription
for the following - alpha-agonist
hypertensives, antidepressants,
anticonvulsants, adrenals, nonsteroidal antiinflammatory agents, anti-inflammatory
agents, and/or vitamins (B, C, D, K, and/or
multivitamin)
QUALITATIVE STUDY
Perceived susceptibility to and
Focus groups
seriousness/severity of breast cancer
recurrence
Perceived benefits of and barriers to
Focus groups
endocrine therapy continuation and adherence
Cues to action that encourage and support ET Focus groups
continuation and adherence
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Research Question
Inclusion/exclusion
criteria; #1, #2, #3
Inclusion/exclusion
criteria
Inclusion/exclusion
criteria
Inclusion/exclusion
criteria, #1, #2, #3
#1, #2, #3
#1, #2, #3
#1 & #3
#3
#3
#3
#3

#4

#5
#6

Appendix C
Recruitment Flyer
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Appendix D
Screening Questions
Hello, (name). Are you calling about the breast cancer study?
Thank you for calling and for your interest in this study. My name is Julie, and I am a
research assistant at Clemson University. How are you today?
We understand that it is a challenge for many women to complete therapy for breast
cancer. We would like to talk to you to find out more about your experience so that we
can help other women in the future. To learn more about your experience, we would like
to schedule a time when you and five or six other women could come and meet together
with us to talk about your experiences.
First, I need to ask you several questions to see if you might qualify for our focus group.
Is that okay?
We will have three different groups that meet, so to determine which group you best fit
in, may I ask you a few questions?
 Were you ever prescribed Tamoxifen?
o If don’t know, ask: Were you ever given a prescription by your doctor
after they completed their initial treatment?
 Do you remember what it was for? (If say, to reduce estrogen or
hormones in the body, then assume Tamoxifen or AI)
 Were you ever prescribed an aromatase inhibitor?
o Probe; (If they don’t know, then list all and ask one by one, e.g.
Anastrozole/Arimidex, letrozole/Femara, or Exemestane/Aromasin?)
<<IF YES, continue with following questions. IF NO, then skip to Option 2,
below…>>
 Did you ever fill your prescription for Tamoxifen (or AI)?
 If yes, for how long did you take Tamoxifen (or AI)?
 Do you remember how old you were when you were first prescribed
Tamoxifen/aromatase inhibitor?
 Are you a female?
 What stage of breast cancer were you diagnosed with?
Eligibility criteria:
 Either prescribed Tamoxifen and/or an aromatase inhibitor: yes
 Female: yes
 Age when began taking Tamoxifen/aromatase inhibitor: 18-64
 English speaker: yes
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 Completed treatment for hormone receptor-positive breast cancer: yes
Option 1 (if eligible to participate in study): Thank you so much for these responses.
(Provide details of appropriate focus group – date, time, and location.) In case something
comes up and you will be unable to attend the focus group, will you please call or text me
at (864)270-3259? Also, to remind you about the event and to send you any updates, may
I ask for your name, phone number, and e-mail address? How would you prefer that I be
in contact with you? Thank you again for your interest and for your willingness to
participate. We hope that our conversation and the information we learn from your
experience can be used to help many other women. At the end of our focus group, we
will be giving you a $50 Walmart gift card to thank you for your time. Do you have any
questions about the focus group? Thank you again for your interest. Have a nice day.
Option 2 (if not eligible to participate in study): Thank you so much for these responses.
Unfortunately, you do not meet the eligibility criteria for our study, so I will not be able
to schedule you to participate in a focus group. (Explain why.) Thank you again for your
interest. Have a nice day.

111

Appendix E
Focus Group Guide
WELCOME
Thank you so much for agreeing to be part of this focus group. We appreciate your
willingness to participate and look forward to a fruitful discussion together.
Today, we are talking with women who are breast cancer survivors, and we are interested
in learning more about your experience.
INTRODUCTIONS
Moderator; assistant moderator
PURPOSE OF FOCUS GROUPS
The reason we are having these focus groups is that it is a challenge for many women to
complete endocrine therapy for breast cancer. When we say endocrine therapy, we are
referring to either Tamoxifen or an Aromatase Inhibitor, medications you may have taken
after your surgery, chemotherapy, radiation, or any other kind of treatment. We want to
find out more about the obstacles that you and other women you know have faced in
order to better aid women in the future. We need your input and want you to share your
honest and open thoughts with us. This focus group will last approximately 1 ½ hours.
Please feel free to get up to go to the restroom anytime. At the end of our time together,
please see [assistant moderator] to receive your $50 Wal-Mart gift card as we value and
appreciate your time today.
GROUND RULES
We would like to address a few important points before we begin.
1. WE WANT YOU TO DO THE TALKING.
We would like for everyone to participate.
We value each of you and your responses. If you have shared a lot, I may call on others
who we haven't heard from in a while so that everyone can have a chance to share.
2. THERE ARE NO RIGHT OR WRONG ANSWERS
Every person's experiences and opinions are important.
Please feel free to speak up whether you agree or disagree.
We want to hear a wide range of opinions.
3. WHAT IS SAID IN THIS ROOM STAYS HERE
We want folks to feel comfortable sharing when sensitive issues come up.
4. WE WILL BE AUDIO RECORDING THE GROUP

112

We want to capture everything you have to say.
We absolutely will not identify anyone by name in our report. You will remain
anonymous. If we use your words we will simply say “one participant told us” – we will
not use your name or describe you in a way that someone could identify you.
So, if you are ready, we will get started with the recording.
Patient introductions/Icebreaker: Please tell us you’re the name that you would like for
us to call you as well as how long ago you were diagnosed with breast cancer.
We understand that you have all had different types of breast cancer treatments, possibly
involving chemotherapy, radiation therapy, or surgery, but we want to spend the rest of
our time together today discussing what happened after these initial treatments.
After your chemo, radiation, or surgery, how many of you received a prescription for
Tamoxifen?
Did anyone receive a prescription for an aromatase inhibitor like Anastrozole/Arimidex,
letrozole/Femara, or Exemestane/Aromasin? Or any other medication?
Did anyone switch from one medication to another? (Probe as to why the switch from one
to the other. What did the new drug do instead?)
Do you remember what type of doctor wrote that first prescription? (Was it your surgeon
or oncologist or a different type of doctor?) During the remainder of our conversation, I
may use the word “provider” when I talk about the doctor since your medical visits may
have been with a doctor, a nurse, a nurse practitioner, or some other healthcare
professional.
Perceived Benefits/Barriers: We understand that when you are finishing up cancer
treatment, you may have lots of different appointments with several different doctors and
that there is a lot of information to take in and decisions to make…We would like for you
to think back if possible to that time when you had finished your chemo, radiation, and/or
surgery and were given the option to take Tamoxifen or an aromatase inhibitor. Tell us
about your experience of going to the doctor and receiving your first prescription. For
example, we would like to hear what you and your doctors discussed, if more than one
doctor talked to you about taking the medication and what those conversations were like,
if you took someone with you to those appointments and what their role was, how you
felt during those appointments, etc.
How often did your doctor say you would need to take the medication each day (whole
pills?), and for how long would you be on the medication?
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(What did you and your providers discuss? Encouraged to fill the prescription and take
the medicine? Comfortable asking questions? Same/different messages from each
provider? Role of the “advocate”?)
Perceived Susceptibility/Seriousness/Severity: At that point when you were first given
your Tamoxifen or aromatase inhibitor prescription, how much did worry about cancer
coming back influence your decision of whether or not to fill the prescription?
We know that all of you did decide to fill your first prescription and took either
Tamoxifen or an aromatase inhibitor, and we want to hear more about your decision
making process. Can you tell us just in your own words more about the benefits you saw
in taking this medication – for example, the purpose of the medication and how you
learned about it?
We know that all of you decided to take the medicine. Can you elaborate more for
us on your experience with taking it - how easy or how difficult if may have been,
and how it impacted your way of life, if at all?
It is a challenge for many women to continue taking their medicine for breast cancer for
a variety of reasons. Based on your own experience or things you have heard from other
women, we would like to brainstorm together why it can be very challenging for women
to take their medicine regularly and stay on it for the duration the doctor recommends.
Ask women to brainstorm.
Prompts if needed:
 Side effects – please describe
 Cost/difficulty getting medicine refilled
 Feeling good so why continue, in denial/want to forget about cancer
 Conflicting advice from doctors/internet/other women
 Sexual problems/fertility concerns
 Developing other health problems or the fear of developing other health
problems
 Can’t avail support services due to work
 Misunderstanding from family/physicians
 Distance from care
We would like to learn more about how it feels talking with your provider about your
medication and any challenges you may have experienced. (Did you wait til you had an
appointment to share your concerns, or did you call ahead of time? Did you feel that
your provider was open to listening to you and to helping you find a way to alleviate
some of the problems you were experiencing? Did you ever feel embarrassed to talk to
the doctor about your concerns? If you decided to stop taking the medicine, did you and
your provider make that decision together or did you make that decision on your own?)
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Next, we want to ask specifically about your experience in getting the Tamoxifen or
aromatase inhibitors with regard to the cost, insurance coverage, and convenience to the
pharmacy, etc.
Please tell us about your experience in getting the medicines with your insurance
coverage. (Any difficulties obtaining the medicines? Any gaps or problems with your
insurance coverage? Did your insurance cover the full expense of your medication? Is
there anything about your experience with your insurance that could have better
supported you if you wanted to stay on the medicine?)
Cues to Action:
We would like to know what suggestions you have that would be helpful to women who
are prescribed these medications and decide to take them daily for the entire duration
needed. If you chose to take the medicine, while you were taking it, what are some things
that were helpful to you? If you did not take the medicine, can you think of anything that
may would be helpful to others? (Things to know before you began taking your
medication, or to help you continue taking your medication? Examples of tried
interventions below if needed.)









Educational pamphlets in the mail (topics: breast cancer, treatments, medication
side effects, strategies for enhancing adherence, and information about diet and
physical exercise)
Monthly reminders in the mail or by e-mail about medication adherence
Phone calls from a nurse to provide motivation, reminders, and individualized
information regarding the patient’s specific problems
Text messaging app that allows the patient to text the provider
Group exercise programs
At home-based exercise programs
Cool pad pillow topper to aid sleep
Meditation training to decrease stress/anxiety

We are getting close to the end of our discussion time. What additional thoughts would
you like to share with the group about your experience with endocrine therapy or any
experiences of other people you know?
Thank the group
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Appendix F
Participant Survey
Thank you so much for your willingness to come and participate in the focus group. We
look forward to our time together and trust that the experiences and ideas you share can
be used to help many women in the future. Below are some short survey questions to give
us a better idea about your history with endocrine therapy.
1. Were you diagnosed with hormone receptor-positive breast cancer?  YES
NO





If yes, what year were you diagnosed? ____________________________



What was your stage at diagnosis?
 Stage 0  Stage I  Stage II  Stage III  Stage IV

2. Have you completed your breast cancer treatment?  YES


 NO

If yes, what year did you complete your treatment? __________________

3. Were you ever prescribed Tamoxifen?  YES

 NO



If yes, did you fill your prescription for Tamoxifen?  YES



If yes, how long did you take Tamoxifen? ____________________________

 NO

4. Were you ever prescribed an aromatase inhibitor? (Aromatase inhibitors include
the following medications: Anastrozole/Arimidex, Letrozole/Femara, or
Exemestane/Aromasin.)  YES  NO



If yes, did you fill your prescription for an aromatase inhibitor?  YES  NO
If yes, how long did you take the aromatase inhibitor? ___________________

5. How old were you when you were first prescribed Tamoxifen or an aromatase
inhibitor? ________
6. What type of insurance did you have while taking Tamoxifen or an aromatase
inhibitor? _________________________________________________________
7. What is your race? __________________________________________________
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8. Education received:
 Some High School
 Associates Degree

 High School Graduate or GED
 Bachelor’s Degree
 Masters or Doctorate
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